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THESIS ABSTRACT 
The World Health Organisation (WHO) recommends the introduction of at least one single dose of 
inactivated polio vaccine (IPV) in routine immunisation schedules to mitigate the risk of a polio virus type 
2 reintroduction or re-emergence. As a result, there has been an increased demand and concurrent 
supply shortages of IPV worldwide resulting in poor access to IPV. With the phasing out of the oral polio 
vaccine and the pursuit of global eradication of polio, ensuring an adequate supply of IPV is of paramount 
importance. One of the strategies to improve access is the use of the fractional dose because of its dose 
sparing and cost reduction properties. This mini-dissertation presents a research protocol (Section A), 
scoping review (Section B) and journal formatted manuscript (Section C) for a systematic review and 
meta-analysis of fractional dose compared to standard dose inactivated polio vaccination in children. 
Section A describes the rationale for the review, eligibility criteria, the search strategy and methods for 
data extraction and analysis. Section B is a scoping review that details the journey towards eradication 
of polio, the current state of IPV demand and supply and further explains the rationale for performing 
the systematic review. Section C is a manuscript that gives the results of the review after performing the 
methods outlined in Section A. The results showed that as the number of IPV doses increased the 
seroconversion rates for fractional dose and full dose IPV approximated each other such that at three 
doses the rates were similar. In conclusion, there is no difference in seroconversion between three doses 
of fractional dose IPV and three doses of full dose IPV. With the current IPV shortages, using fractional 
dose IPV instead of the full dose IPV can stretch supplies and possibly lower the cost of polio vaccination.  
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1.  INTRODUCTION 
Poliomyelitis (or polio) is a communicable disease caused by one of three related wild polioviruses: 
poliovirus types 1, 2 and 3. Infection can occur at any age, but it mainly affects children under five.1 The 
virus typically enters the body through the mouth and multiplies inside the gut. Initially it manifests as 
flu-like symptoms. Once established, it enters the bloodstream and attacks the central nervous system. 
As it proliferates, it destroys nerve cells which stimulate muscles. These nerve cells cannot be renewed, 
and affected muscles no longer function; causing paralysis. Up to 95% of infected individuals are 
asymptomatic and about 5% who develop minor flu-like symptoms fully recover.2 Paralysis occurs in less 
than 1% of infected individuals.2 Immunity against polio comes from either natural infection, which is 
when one recovers from polio or is immunised against contracting the disease through vaccination. 
There are two polio vaccines which are highly effective. The first is an injectable vaccine developed in 
the 1950s (the inactivated poliovirus vaccine) and the second an oral vaccine developed in the 1960s 
(the oral polio vaccine).1 
In the early 1980s, more than 350 000 cases of paralytic polio were estimated to occur per year 
worldwide.3 The widespread use of the oral poliovirus vaccine (OPV) resulted in substantial advances 
towards eradicating polio.3-5 However, the vaccine has been associated with vaccine associated paralytic 
poliomyelitis (VAPP) and the generation of vaccine derived polioviruses (VDPVs).6,7 These liabilities 
threaten the achievement of a polio free world. The Polio Eradication and Endgame Strategic Plan 2013-
2018 outlines the necessary steps required to ensure that transmission of both wild polio viruses (WPV) 
and VDPVs is interrupted. One of its objectives is to prevent spread and re-emergence of VDPVs by 
gradually replacing OPV with the inactivated poliovirus vaccine (IPV).8 The first stage in the phased 
removal of OPV was completed in April 2016.9 It involved the cessation of the type 2 component of OPV 
through a global switch from trivalent OPV (tOPV) to bivalent OPV (bOPV).8 
Prior to switching, in November 2012, the Strategic Advisory Group of Experts on Immunization (SAGE) 
recommended the introduction of at least one dose of IPV in national immunisation schedules to 
mitigate the risk of re-introduction or re-emergence of WPV type 2 or VDPV type 2.10 This dose was 
meant to provide an immune base to improve immunological reactions and lower the risk of paralysis in 
the event of a type 2 polio outbreak.3,11 In its 2016 polio vaccine position paper, the World Health 
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Organisation (WHO) endorsed the recommendation.3 Globally, the demand for IPV increased globally 
from 80 million doses in 2013 to 200 million doses in 2016.12 The global manufacturers that had assured 
the Global Polio Eradication Initiative (GPEI) and its partners about the feasibility of scaling up production 
to meet the demand, only managed to supply about half of the required doses for 2016 and 2017 and 
the supply is deteriorating.12,13 With the limited supply and lack of competition in the market, the cost 
of IPV (up to US$ 2.8 per dose)13,14 further restricts access in resource-constrained countries.  
IPV shortages and high cost have given rise to delayed IPV introduction in some countries, while 
countries that already have IPV as part of their schedule are experiencing stock outs.15,16 By September 
2016, about 105 out of 126 countries that had OPV-only immunisation schedules had introduced IPV.16 
According to an update from UNICEF in March 2017, there were 18 countries that had introduced IPV 
which were only to receive IPV shipments in the first half of 2018.18 Going forward, after the expected 
certification of global polio eradication in 2022, IPV will be the only vaccine being used.19 This puts 
pressure on both the global community and individual countries to come up with strategies to ensure 
affordable and reliable long-term supply of IPV. 
To address the current shortages and ensure availability of IPV, the GPEI and its partners are using a 
multipronged approach.16 One of the recommended strategies is the use of dose sparing fractional doses 
instead of full doses of IPV.3,16 One fractional dose (0.1ml) is one fifth of the full dose (0.5 ml) and it is 
usually delivered using an intradermal injection. Several randomised studies have assessed the 
immunogenicity of fractional-doses of IPV (f-IPV) compared to full dose(s) of IPV.20-23 Randomised studies 
done in Cuba,20,22 Oman21 and Bangladesh23 have shown that two fractional doses of IPV result in a better 
immunogenicity than one full dose of IPV. 
Vaccination invokes a humoral immune response producing antibodies which, in most cases, offer long 
term protection against polio viruses.3 Intradermal delivery of the polio vaccine is an efficient and 
effective mode of vaccination because it allows for the dose sparing approach.24,25 Due to the abundance 
of immune cells in the dermis, when a vaccine is given via the dermis, a lower dose can be used compared 
to the intramuscular and subcutaneous routes.25 In terms of cost, the price of one fifth of the dose is 
expected to be a fifth of the price of the full dose; hence reducing the cost.4 According to an assessment 
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that was done by PATH, two f-IPV doses and the intradermal injection devices cost between US$1 to 
US$3 while a single intramuscular dose of IPV costs between US$ 1.1 and US$2.3.25 
This dose sparing strategy might be the immediate solution to ensure that every child who is entitled to 
receive IPV is vaccinated. India and Sri Lanka have already introduced the f-IPV doses in their routine 
immunisation schedules with notable successes. In both countries, they have managed to vaccinate a 
larger number of eligible children while stretching their stocks; subsequently avoiding stock outs.16 A 
mass vaccination campaign using a single f-IPV was successfully carried out in response to a VDPV type 
2 outbreak in the Telangana State of India in May 2016.26 
Countries are encouraged to consider the programmatic and logistic challenges that come with 
introducing f-IPV before rolling out the policy.3 Intradermal administration involves purchasing of 
devices to administer, training health workers and other logistics which affect the feasibility of the 
programme.17 Programmes in India and Sri Lanka have demonstrated that despite these challenges, a 
nationwide programme using f-IPV is possible even in an outbreak setting.16,26 
The Sustainable Development Goal number 3 includes achieving access to affordable, safe and effective 
vaccines for all by 2030.27 Replacing OPV with IPV is essential for the eradication of WPV and VAPP. As 
we progress towards the certification of the global eradication of polio, ensuring sustainable, reliable 
and affordable IPV supply is of paramount importance. The dose sparing, and cost reduction 
characteristics of fractionated doses can contribute to improved IPV access. This review will add to the 
evidence gathered by other reviews to inform decisions regarding the value of fractionated IPV dosages. 
Grassly28 performed a systematic review and meta-analysis to assess the immunogenicity and 
effectiveness of 1 or 2 doses of f-IPV in routine immunisation. The author found that two f-IPV doses 
administered after 10 weeks of age are likely to provide 80% protection against poliomyelitis. It is now 
5-6 years since the literature search was conducted for this review, and new evidence has accumulated 
since then.23,26 In addition, study selection and data extraction were not done in duplicate; increasing 
the risk of systematic errors in this timely review.28 It is an indispensable practice in systematic reviews 
to conduct those steps in duplicate, and resolve discrepancies by discussion and consensus or 
arbitration.29 
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In another review, Anand et al.11 focused on comparing immunogenicity of two f-IPV and one full dose 
of IPV. They concluded that two f-IPV doses are more immunogenic than a single dose. Of note, in both 
reviews,11,28 there is absence of an extensive search of the literature. This evidenced by a limited number 
of databases searched by the authors. Grassly searched only the Web of Knowledge collection of 
databases and Anand and colleagues’ search was restricted to the PubMed database only. Therefore, 
there might be other studies that were excluded from these reviews that may alter their findings. 
Vaccine safety and administration are important considerations when deciding on an immunisation 
schedule. The previous reviews did not evaluate adverse effects of different IPV dosages and the devices 
used to give the intradermal injections. In addition, none of the previous reviews used the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) method30 to assess the certainty 
of the evidence on effects of f-IPV. 
We aim to do a systematic review of studies comparing the effects of fractional compared to full dose 
IPV vaccination. We will evaluate the occurrence of adverse events and document the types of 
administration devices used for the intradermal delivery of f-IPV.  
2.  OBJECTIVES 
The objective of this review is to assess the effects of fractional doses of inactivated polio vaccine, 
compared full doses of the vaccine. 
3.  METHODS  
3.1  Criteria for considering studies for this review 
3.1.1  Types of studies 
We will include randomised trials, non-randomised trials, case-control studies and cohort 
studies.  
3.1.2  Types of participants 
The participants of interest will be children aged five years of age or younger.  
3.1.3  Types of intervention 
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The eligible intervention will be the administration of fractional dose(s) of IPV, while the 
eligible comparison will be the administration of full dose(s) of the vaccine; irrespective of 
vaccination schedule or route of administration. Only studies comparing the same number 
of doses of fractional versus full doses of IPV will be compared.  
3.1.4  Types of outcome measures 
The primary outcome for this review is immunogenicity, measured using the proportion of 
participants who sero-converted (as defined by the authors of the included studies). As well 
as titres of poliovirus-neutralising antibodies for wild poliovirus serotypes 1, 2, and 3; 
assessed at least four weeks following vaccination. Our secondary outcomes include adverse 
events following polio vaccination; vaccine associated paralytic polio; and wild poliovirus 
associated paralytic polio and mucosal immunity (as defined by the authors). We will also 
describe the routes and devices used to administer the fractional doses of the vaccine. 
3.2  Search methods for identification of studies 
We will develop a comprehensive search strategy for peer-reviewed and grey literature. We will 
search the following databases from the inception to the date of the search; with no date or 
publication restrictions: Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, 
EMBASE, Science Citation Index, Conference Proceedings Citation Index, Cochrane Database of 
Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effectiveness (DARE), Scopus, 
EBSCO Host: AWI, CINAHL, Health Source: Nursing/Academic Edition, PDQ-Evidence, Network of 
Digital Library of and Theses and Dissertation, DART Europe E-theses Portal, ProQuest Dissertations 
& Theses A&I, PapersFirst (OCLC), Proceedings (OCLC), and the WHO International Clinical Trials 
Registry Platform (ICTRP). We will also search the reference lists of included studies, related 
reviews, and relevant WHO vaccine position papers. Table 1 below shows the proposed search 
strategy for the PubMed database, which will be adapted for the other databases. 
 
Table 1. PubMed search strategy 
#1: Poliovirus Vaccine, Inactivated [MeSH] OR inactivated polio vaccine OR inactivated poliovirus 
vaccine OR SALK OR IPV OR eIPV OR killed vaccine. 
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#2: Injections, Intradermal [MeSH] OR Injections, Intramuscular [MeSH] OR fractional dosing OR 
Fractionated dosing OR drug dose comparison OR intradermal OR intramuscular OR dose OR dosage. 
#3: Dose-Response Relationship, Immunologic [MeSH] OR Antibody Formation [MeSH] OR 
Seroconversion [MeSH] OR Immunogenicity OR Immune response OR Seroconversion OR potency OR 
antibody formation OR antibody response. 
#4: (#1 AND #2 AND #3). 
#5: Animals NOT Human 
#6: (#4 NOT #5) 
3.3  Data extraction and management 
For each included study, two authors will independently extract the information indicated in Table 
2 using a pre-designed and piloted data extraction form. Extracted data will include study, 
participant, intervention, and outcome characteristics as well as study findings (Table 2). We will 
present this information in a table of the characteristics of included studies. Any differences will 
be resolved through discussion and consensus between the two authors. A third author will be 
consulted to arbitrate if disagreements persist between the two authors. If there are missing data, 
we will contact study investigators for the missing information. 
Table 2. Information that will be extracted from each included study 
Study design 
and methods 
Citation information (authors, journal, year of publication, volume, issue, and page 
numbers); study design (randomised trial, non-randomised trial, case-control study, 
cohort study); study location (city, country), and period of study (start and end date 
i.e. month and year).  
Methods for generating randomisation sequence, concealing allocation of 
interventions, and blinding of outcome assessment; number of participants 
randomised and number with complete outcome data for each outcome; names of 
outcomes announced in study protocol but not reported in study publication, and 
other biases. 
Participant 
characteristics 
Age, sex, study location, study inclusion and exclusion criteria, flow of numbers of 
participants during the study (from participant enrolment to completion of data 
collection). 
Intervention  Definition of fractional dose, manufacturer of vaccine, immunisation schedule 
(frequency, timing, interval between doses, etc), OPV co-administration, route of 
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administration (intradermal, sub-cutaneous, etc), and types of devices used for 
administration of the fractional doses (name, manufacturing company, etc). 
Comparison Definition of full dose, manufacturer of vaccine, immunisation schedule (frequency, 
timing, interval between doses, etc), OPV co-administration, route of 
administration (intramuscular, sub-cutaneous, etc). 
Outcome 
measures 
Outcomes reported in the study (immunogenicity, adverse events following polio 
vaccination, vaccine associated paralytic polio, wild poliovirus associated paralytic 
polio, mucosal immunity), how they were defined, and how they were measured.  
Outcome data Seroconversion (number of participants randomised and number who 
seroconverted in each arm), antibody titres (geometric mean plus standard 
deviation or median and range in each arm), number of participants randomised 
and number who experienced the following events in each arm: adverse events 
following IPV vaccination, vaccine associated paralytic polio, wild poliovirus 
associated paralytic polio, mucosal immunity). 
 
3.4  Assessment of risk and bias in included studies 
Two authors will independently assess the risk of bias for each included study using the Cochrane 
Risk of Bias tool for trials31 and the ROBINS-I tool non-randomised studies of interventions.32 For 
trials, we will assess the risk of bias across seven domains: random sequence generation, allocation 
concealment, blinding of participants and study personnel, blinding of outcome assessment, 
incomplete outcome data, selective outcome reporting and other potential source of bias. For each 
included study, whether trial or not, we will describe what the study authors reported that they 
did for each domain and then assign a judgement of low, high, or unclear risk of bias. Differences 
in judgement will be resolved by discussion and consensus, or arbitration by a third author. Based 
on these assessments, we will classify each included study as having a low, moderate, or high risk 
of bias. Each study that receives a judgement of high risk for allocation concealment, blinding of 
outcome assessment, or completeness of outcome data will be considered to have a high risk of 
bias. A study that is judged to have low risk of bias for all three domains will be considered to have 
a low risk of bias. All other studies will be considered to have a moderate risk of bias. We will use 
these risks of bias data in the GRADE assessments of certainty of evidence, as described below, by 
downgrading the certainty of the evidence of effects from trials with high risk of bias.  
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3.5  Dealing with missing data 
For incomplete or missing data, we will contact corresponding authors to request additional 
information or clarification. Missing data and dropouts will be reported in the ‘risk of bias’ table 
and we will evaluate the impact of missing data on our results. Where possible we will conduct 
intention to treat analysis (ITT). We will conduct sensitivity analyses were by missing data is treated 
as successes or failures (worst-best and best-worst case scenario sensitivity analysis).  
3.6  Data Synthesis 
We will stratify the analyses by the type of study design, type of poliovirus, type of outcome 
measure, and number of IPV doses given. We will use the risk ratio (RR) and its corresponding 95% 
confidence interval to summarise data for the following binary outcome measures 
(seroconversion, adverse events following polio vaccination, vaccine associated paralytic polio, 
wild poliovirus associated paralytic polio and mucosal immunity). For geometric median titres (our 
only outcome measure with continuous data), we will calculate the mean difference (MD) and its 
95% confidence interval when the outcome data is measured on the same scale. Alternatively, if 
the measurement scale differs, the standardised mean difference (SMD) and its 95% confidence 
interval will be used. 
For each type of poliovirus, we will pool the outcome data from studies with the same design and 
amount of IPV doses administered using the random-effect method of meta-analysis. In studies 
where there are multiple interventions, we will include pair-wise comparisons that address the 
objectives of our review as outlined above. To avoid double counts when analysing correlated 
groups, we will pool the groups together to create a single pair-wise comparison 
3.7  Assessment of heterogeneity 
Initially we will assess for heterogeneity by visually inspecting the forest plots for overlapping 
confidence intervals. To further evaluate statistical heterogeneity, we use the χ2 test of 
homogeneity; with significance defined at the alpha level of 0.10. We will also use the I2 statistic 
to quantify the amount of heterogeneity.33 We will investigate the causes of statistical 
heterogeneity using subgroup analyses.  
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We will define subgroups based on the timing of the first fractional dose, age of administration, 
number of fractional doses, interval between doses, poliovirus type (1, 2 and 3), type of 
intradermal injection device, immunisation schedules (OPV containing versus non-OPV schedules), 
and country income status.34 
3.8  Assessment of reporting biases 
We will reduce possible publication bias by using a comprehensive search strategy. Literature 
sources will include published, unpublished, and grey literature. To investigate possible publication 
bias, we will construct funnel plots if there are more than 10 studies included in the meta-
analysis.35 
3.9  Sensitivity analysis 
We will perform sensitivity analyses to assess if the effect of f-IPV will be affected by of bias (by 
excluding studies with a high risk of bias), study designs (randomised versus non-randomised), and 
methods of meta-analysis (fixed versus random effects). 
3.10  Reporting review findings  
We have written this protocol, and we will report the outcome, following the recommendations 
of relevant PRISMA guidelines.36-38 Additionally, forest plots and GRADE summary of findings tables 
will be used to report the outcome of our analysis. We will use the GRADE approach to evaluate 
the certainty of the evidence.  
The GRADE approach assesses the certainty of a body of evidence as high, moderate, low, or very 
low; through evaluating the risk of bias, imprecision, inconsistency and indirectness of study 
results, and the risk of publication bias.39,40 Regarding risk of bias, concerns that will limit our 
confidence in the evidence of effects are lack of allocation concealment, lack of blinding of 
outcome assessment, and differential losses to follow-up between intervention and comparison 
groups of more than 10%. Inconsistency of effects across included studies, for which we find no 
compelling explanations, will reduce our confidence in the evidence. Indirectness occurs when 
there are differences between the participants, interventions, comparisons, and outcomes of a 
Section A: Research protocol 
11 
 
review, and those reported in included studies. We do not anticipate that this will be an issue in 
our planned review. For imprecision, if we obtain pooled estimates of effects with wide confidence 
intervals (a situation which occurs when included studies have small number of participants and 
experience few events), we will rate down the certainty of the evidence. Finally, we will downgrade 
the certainty of evidence of effects of f-IPV if our funnel plots show a high likelihood of publication 
bias. 
4.  ETHICS AND DISSEMMINATION 
Collection of data for our review does not involve direct contact with human participants. Instead will 
use published and publicly accessed data. We obtained approval from the University of Cape Town 
Human Research Ethics Committee (HREC REF: 412/2018). We registered the review in the PROSPERO 
International Prospective Register of Systematic Reviews (CRD42018092647). The findings of this review 
will provide policy makers, health workers and donors with evidence for decision making with regards 
to IPV dosage. In the face of the current shortages, this might improve immediate and long-term access 
to the vaccine. The results of the review will be published in the University of Cape Town online library 
and published in a peer reviewed journal. 
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THE JOURNEY TOWARDS ERADICATING POLIO: IS THERE A ROLE FOR FRACTIONAL 
DOSAGE OF INACTIVATED POLIOVIRUS VACCINE? 
 
1.  INTRODUCTION 
Walking the last mile towards polio eradication, requires interruption of wild poliovirus (WPV) 
transmission in the remaining endemic countries (Pakistan, Afghanistan and Nigeria) and cessation of 
oral poliovirus vaccine (OPV) use to interrupt transmission circulating vaccine derived polio virus 
(cVDPVs).1,2 The stepwise removal of OPV has been affected by the increased demand and the short 
supply of inactivated poliovirus vaccine (IPV).3 Currently a few countries have taken the initiative to 
introduce fractional-dose inactivated poliovirus (f-IPV) in their national immunisation schedules in place 
of the recommended full dose to ease the shortages.  
This scoping review gives an account of the journey towards eradicating polio including an update on 
the current state of IPV supply and the rationale for performing a systematic review that compares f-IPV 
to the recommended standard dose.  
To identify relevant literature for the scoping review, the search strategy outlined in table 1 of Section A 
(Research protocol) was used in PubMed and was adapted for the Cochrane Database of Systematic 
Reviews (CDSR), EBSCOhost and ProQuest Dissertations & Theses A&I databases. All literature that was 
related to reduced dose or intradermal delivery (ID) of IPV was included in the scoping review. The 
literature is explored in detail in Section 6 of the review which describes the study rationale.  
Additional searches were performed to put this scoping review into context. Key phrases such as “history 
AND poliomyelitis”, “global eradication AND poliomyelitis”, “fractional IPV AND shortages” and 
“transition phase AND poliomyelitis” were used in PubMed, Google, Google scholar and World Health 
Organisation (WHO) and Global Polio Eradication Initiative (GPEI) web sites. References of included 
articles were also searched for relevant citations.  
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1.1  Background 
1.1.1  What is Polio? 
Poliomyelitis (polio) is an acute enteric viral infection that commonly affects children under 
the age of 5 years. 4,5 The disease is caused by any one of the three wild polioviruses (WPV) 
– WPV 1, WPV 2 and WPV 3.5 These viruses can affect the nervous system leading to 
debilitating paralysis or even death.4,6 Transmission of the virus is mainly through the faecal-
oral route.  
After the virus enters the host, it multiplies within the intestines and spreads to the blood 
stream causing viremia.4 Clinical symptoms typically manifest after about 7 to 10 days.6,7 
Amongst infected individuals, 90-95% are asymptomatic and the 5% who develop minor flu-
like symptoms fully recover.8 Less than 1% of infected individuals develop an irreversible 
asymmetric paralysis in the lower limbs which continues to spread upwards as other parts of 
the nervous system are affected.5,8 Diagnosis of paralytic polio can be either clinical or 
through laboratory techniques that isolate and identify the viruses. There is no cure for polio, 
treatment is focused on supportive management that limits disease progression and 
prevents skeletal deformities.4,8 
1.1.2  Polio vaccines 
Prevention through vaccination remains the key strategy in the fight against polio. There are 
two types of polio vaccines: the inactivated poliovirus vaccine (IPV) and the oral poliovirus 
vaccine (OPV). The key attributes of each vaccine are listed in table 1 below. OPV has 
contributed significantly to the eradication of polio. Compared to IPV, OPV has a lower cost, 
is easily administered orally and generates an enhanced mucosal immunity.6,9 It is not 
surprising that it quickly became the vaccine of choice particularly in low-income countries. 
The association of OPV with a small risk of vaccine derived paralytic poliomyelitis (VAPP) 
caused by vaccine derived polioviruses (VDPVs)10 has paved a way for IPV to be the vaccine 
of choice as the world pursues global eradication of polio. 
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Table 1. Key attributes of OPV and IPV 
OPV IPV 
▪ Oral, live attenuated vaccine ▪ Injectable, inactivated vaccine 
▪ Produced from attenuated Sabin strains* ▪ Produced using antigens from wild poliovirusesꝉ 
or from attenuated Sabin strains. 
▪ Induces humoral immunity  ▪ Induces humoral immunity  
▪ Induces mucosal immunity  ▪ Little or no direct effect on mucosal immunity 
but boosts immunity in those previously exposed 
to OPV. 
▪ Induces life-long immunity 
▪ Promotes herd immunity 
▪ Induces life-long immunity 
▪ Less likely to promote herd immunity 
▪ Low risk of VAPP and VDPV ▪ Absent risk of VAPP and VDPV 
▪ Low cost ▪ Expensive 
▪ Easier to administer ▪ Requires skilled personnel to administer 
OPV = oral poliovirus vaccine; IPV = inactivated poliovirus vaccine; VAPP = vaccine derived paralytic poliomyelitis; VDPV = vaccine 
derived poliovirus 
*3 vaccine strains (Sabin1, 2 and 3) derived from attenuation of the parent wild poliovirus. 
ꝉ Antigens for the vaccine are made from WPV strains – Mahoney or Brunhilde (type 1), MEF (type 2) and Saukett (type 3). 
Data for the table extracted from the WHO position paper on Polio vaccines - March 2016.6  
2.  POLIO THEN – THE HISTORY OF POLIO 
2.1  A time calamity 
Polio has an intriguing history that has been well documented throughout the years. Suggestion of 
its existence dates to 1580-1350BC.11 This evidence comes from an Egyptian stele which shows a 
priest with a withered leg that resembles the clinical presentation of polio.11,12 The disease only 
became a public health concern in the 1890’s and early part of the 20th century when North 
America, Europe and some Scandinavian countries experienced a significant increase in polio 
outbreaks.11,13,14 Nathanson and Kew12 suggest that the sudden surge in polio outbreaks was due 
to delayed infection secondary to improved hygiene and sanitation. 
As the years progressed, the epidemics became more frequent and severe.15 Surprisingly, 
compared to other diseases, the incidence of polio was relatively low.12,15 Instead, it was the 
physical effects of polio that instilled a lot of fear, anxiety and panic among parents, communities 
and government officials. These effects included death, being confined to wheelchairs and the use 
of splinters, casts and iron lungs to counteract muscle paralysis (figure 1A and 1B below). Because 
of this calamity, the first half of the 20th century was filled with significant research on polio which 
contributed to finding a lasting solution to this crippling disease. 11,14,16 
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2.2  Success in the Americas 
A breakthrough came in 1955 when Dr Jonas Salk, in one of the largest vaccine trials in history, 
proved that his formalin-inactivated polio vaccine resulted in 60-90% immunity against all three 
polio viruses.17,18 In addition to its size, what made Salk’s study unique was the magnitude of public 
participation and political willingness. The research was funded by the public through drives that 
were coordinated by the National Foundation of Infantile Paralysis which later became the March 
of Dimes.14,18,19 The organisation was born out of United States of America (USA) President Franklin 
Roosevelt’s quest to fight polio in 193819 (figure 1B below). History suggests he had suffered from 
polio which left him paralysed.14,19 Following the publication of the trial results, IPV was licenced 
on the 12th of April 1955 and within two weeks it had been rolled out within the USA.18 
The controversy between the use of a killed virus by Salk and the use of the tried and tested live 
attenuated virus resulted in Dr Albert Sabin and colleagues forming another polio vaccine.8,18,20 
Sabin’s oral live attenuated vaccine trials were successfully done in the Soviet Union in the late 
1950’s.8 In 1960, he published ground-breaking results that showed the safety and effectiveness 
of OPV in South America.8,21 Sabin’s OPV had an added advantage over Salk’s IPV which included 
ease of administration, superior immunity and ability to induce mucosal immunity.8,22 OPV was 
licenced in USA in 1961 and in the following 3 years it gradually replaced Salk’s IPV.8,13,20  
Figure 1. The effects of polio on children (1A and 1B) and the exponential decrease of cases after the 
introduction of IPV and OPV in USA (C)  
1A. 
 
1B. 
 
1C. 
 
IPV = Inactivated poliovirus vaccine; OPV = Oral poliovirus vaccine; USA = United States of America 
1A- Children in a hospital using iron lungs to breathe. Picture accessed from GPEI website.11  
1B- President Roosevelt dining with polio patients in Georgia. Picture from an article on polio by Leah Libresco.23  
1C- Exponential decline in reported cases of poliomyelitis in the United States, 1951–1982 after IPV and OPV.12  
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Both IPV and OPV resulted in a 90% reduction in the incidence of polio15 such that by 1973 polio 
had been eradicated in North America11 (see figure 1C above). This exponential decline in the 
number of deaths and cases of paralysis in the USA motivated other countries experiencing 
outbreaks in the Americas to pursue eradication of polio. It was through the combined effort of 
organisations such as the Pan American Health Organisation (PAHO), Rotaract International, 
United Nations International Children's Emergency Fund (UNICEF) and WHO together with 
individuals like Dr Sabin, Ciro A. de Quadros and Rodolfo Rodriguez Cruz that led to the eradication 
of polio in the Americas.15,24,25 
de Quadros, Cruz and colleagues used lessons learnt from small pox eradication as a guide to 
implementing polio eradication strategies in the Americas. The use of mass immunisation was 
instrumental in the eradication of polio in the Americas (figure 2A below). Cuba was the first 
country to use mass vaccination in 1962 and between 1962 and 1978 there were only 5 cases of 
polio and no deaths were reported.11,15,24 After failing to interrupt polio transmission through 
routine immunisation, Brazil, in 1980, added national immunisation days which proved to be a 
great success.15 
Encouraged by the success in Cuba, Brazil and Mexico, PAHO in 1985 resolved to interrupt the 
transmission of wild poliovirus in the Americas by the end of 1990.8,15,25 From then on, other 
countries in the Western hemisphere started using similar strategies as those used by the 3 
countries mentioned above. These strategies included mass vaccination, routine immunisation, 
polio surveillance and mop up strategies.15,25 OPV, because of the advantages stated above, 
became the vaccine of choice for campaigns and routine immunisations.  The last case of polio in 
the WHO region of the Americas was in 1991 and in 1994 the region was certified polio free.11  
2.3  Polio Eradication becomes a global quest 
From the beginning of the outbreaks in the Americas, it was perceived that the incidence of polio 
was low in developing countries.26,27 The lameness surveys done in the 1970’s proved 
otherwise.26,27 The incidence of polio in some of the countries was found to be as high as USA’s 
incidence during the pre-vaccine era.26,27 In 1974, the WHO established the Expanded Programme 
on Immunisation (EPI).28 This was the first step in taking polio eradication global. The EPI ensured 
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consistent vaccination against vaccine preventable diseases, including polio, worldwide.28 Inspired 
by the success in the Americas and the eradication of small pox, in 1988 the World Health Assembly 
(WHA) committed to global eradication of polio by the year 2000.29,30 The Global Polio Eradication 
Initiative (GPEI), a partnership between national governments and global partners, was then 
formed to facilitate the realisation of this goal.11 
Figure 2. The effect of mass vaccination on the number of countries with indigenous virus (1985-2010) 
(2A) and global polio immunisation coverage and reported from 1990 to 2016 (2B).  
2A. 
 
2B. 
 
 
2A - Countries with wild poliovirus circulation deacreased as mass vaccination campaigns increased, 1985–2006. Graph 
accessed from a review by Aylward B. and Tangermann R. on the Global Polio Eradication Initiative.31  
2B- A bar graph showing global decline of reported cases of polio and a line graph showing the increase in coverage of the 
third dose of polio vaccine from 1980 to 2016. The graph was accessed from WHO website.32  
From the time the GPEI was formed up to now, there has been many successful efforts towards 
achieving global polio eradication. Global cases of polio have reduced from over 350 000 cases in 
1988 to just 22 cases in 20175 (see figure 2B above). This 99.9% reduction in the global incidence 
of polio and the prevention of over 16 million cases of paralysis has resulted in the saving of up to 
US$27 billion globally.6,33 In 1988, more than 125 countries reported cases of polio but now only 
three countries, Nigeria, Pakistan and Afghanistan, still have endemic polio6 (figure 3 below).  
The WHO Western Pacific region was certified polio free in 2000, followed by the WHO European 
region in 2002.11 Eradicating polio in India and the declaration of the South East region as polio 
free in March 201434 further strengthened and reassured everyone that a world without polio is a 
possibility. Amongst the reported cases, WPV 1 remains the only cause of indigenous polio.5 WPV 
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3 was last seen in November 2012 in Nigeria while WPV 2 was last detected in India in 1999.5,6 
WPV 2 eradication was eventually certified in September 2015.35,36  
Figure 3. Achievements towards global eradication of polio: a map of endemic and polio free countries. 
    
     
 
Only Nigeria, Pakistan and Afghanistan are the remaing endemic countries. The map was accessed from Our world in Data 
website.37 
 
3.  POLIO NOW 
3.1  Polio fights back 
The containment of WPV transmission over the years has forced the polioviruses to evolve in order 
to survive.8 Continuous replication in the intestines or continuous circulation within a community 
of the attenuated Sabin strains in OPV results in genetic mutations which cause the strains to re-
acquire their neurovirulence and transmissibility characteristics.10,38,39 For this reason, OPV has 
been associated with VAPP and the generation of VDPVs.8,38 It is estimated that there are 2-4 cases 
of VAPP per million birth cohort per year.10 VAPP is indistinguishable to the paralytic poliomyelitis 
caused by WPV and the management is similar.38,40  
The existence of VDPVs is a major public health concern and affects current and future strategies 
for eradicating polio.2,10,38 Of the three types of VDPVs that exist (table 2 below), cVDPVs have 
given rise to many polio outbreaks for the past 20 years.39,41 From 2000 up to 2015, there were 24 
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cVDPV outbreaks in 21 countries resulting in about 760 cases of VAPP.39,41 The largest outbreak 
spanned from 2005 to 2014 in Northern Nigeria with over 400 reported cases.40,42,43 
Table 2. Types of vaccine derived polioviruses (VDPVs) 
▪ Circulating VDPVs (cVDPVs): arises from sustained circulation of vaccine derived virus 
through transmission from one person to another.  
▪ Immunodeficiency VDPVs (iVDPVs): arises from continuous replication of vaccine derived 
virus in a person with primary immune deficiency. 
▪ Ambiguous VDPVs (aVDPVs): a virus that is vaccine derived that is not related to 
immunodeficiency and outbreaks or an environmental isolate whose source is unknown. 
Data for the table adapted from review by Kew et al.8 on VDPVs and polio eradication. 
cVDPV from the type 2 Sabin strain is the main cause of outbreaks44 (figure 4 below). By 2015, the 
type 2 cVDPV accounted for approximately 90% of cVDPVs39,44 and 26-31% of VAPP cases.10 Since 
the beginning of 2018, outbreaks have been reported in the Democratic Republic of Congo, 
Somalia and Nigeria.42 The type 2 cVDPV isolated from the outbreak in Somalia is linked to an 
isolate that was detected in Kenya in March 2018; indicating the possibility of a regional spread in 
the Horn of Africa.45 cVDPVs outbreaks are still occurring46 therefore, cessation of OPV use is a key 
aspect in ensuring elimination of cVDPVs transmission. 
Figure 4. Circulating vaccine-derived poliovirus cases detected, by serotype — worldwide, January 2000–
June 2017  
        
 
cVDPV = circulating vaccine-derived poliovirus; OPV = Oral polio vaccine. A bar graph showing that most of the detected case 
are cause by cVDPV type2. Graph assessed from an update on Vaccine-Derived Polioviruses by Jorba et al.44 in 2017. 
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3.2  New strategy, renewed hope – The Polio Eradication & Endgame Strategy 2013-2018. 
Considering that cVDPV from the type 2 Sabin strain is the main cause of VAPP and cVDPV 
outbreaks (figure 4 above), eradication of WPV type 2 in 1999 provided a platform for GPEI to 
simultaneously interrupt transmission of both WPVs and cVDPVs.9,31,47,48 The Polio Eradication and 
Endgame Strategic plan 2013- 2018, outlined the necessary steps towards achieving this goal.2 
Objective 2 of the strategy was to gradually remove OPV and replace it with IPV.2 The first step in 
the phased removal of OPV was the cessation of the type 2 component of OPV through a global 
switch from trivalent OPV (tOPV) to bivalent OPV (bOPV).2,49 By April 2016, all the all OPV-using 
countries had successfully switched to bOPV. 50,51 Since then, the detection of type 2 isolates has 
been gradually decreasing52 (see figure 5 below). 
Figure 5. Number of poliovirus type 2 isolates from persons with acute flaccid paralysis or their 
contacts and from sewage samples in countries where mOPV2 was not used after the global 
synchronized switch from tOPV to bOPV — January 2016–March 2017  
 
 
 
bOPV = bivalent oral poliovirus vaccine; mOPV2 = monovalent oral poliovirus vaccine type 2; tOPV = trivalent oral poliovirus 
vaccine. The histogram shows a gradual global decline in of type 2 isolates detected from samples collected for surveillance  
The graph was accessed from a report about the virologic monitoring of type 2 polio virus by Diop et al.52  
3.3  One step forward, one step behind – The effects of IPV shortages. 
To mitigate the risk of re-emergence and outbreaks of type 2 polio virus (wild or vaccine derived), 
in November 2012, Strategic Advisory Group of Experts on Immunization (SAGE) proposed the 
introduction of at least 1 dose of IPV in immunisation schedules.53 The dose of IPV would prime 
individuals or create an immune base that would ensure a quick response to vaccination and 
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reduce the likelihood of developing paralysis following type 2 polio infection.6 Though the 
recommendation was vital and in line with the phased replacement of OPV with IPV, 
implementation has been constrained by the global shortages of IPV that came after. As countries 
started making plans to introduce IPV into their schedules, the demand for IPV increased 
exponentially from 80 million doses in 2014 to 120 million doses in 2016.51,54 On the supply end, 
manufactures who had assured UNICEF and other global partners of their ability to scale up 
production failed to meet their targets.3 From 2014 to 2018, only 46% of the contracted quantities 
were supplied3 (figure 6 below). Unanticipated procedural difficulties of scaling production and the 
unexpected increase in IPV use in outbreaks were the main reasons for the shortages.3  
Figure 6. Long-term arrangements between UNICEF and suppliers versus actual and forecast supply 
2014-2018  
 
 
 
A bar graph showing the difference between the long-term supply arrangement between UNICEF and IPV suppliers and the 
actual supply that UNICEF received. The graph was accessed from an update on Inactivated Polio Vaccine supply by the 
UNICEF Supply Division (May 2018).3 
The effects of these shortages included – a. delayed implementation of IPV introductions, b. drug 
stock outs in countries that have already introduced IPV in their schedules and c. depleted global 
reserves for outbreaks.51,55,56 Amongst countries that secure IPV through UNICEF, 18 have delayed 
IPV introduction and 17 have delayed resupply3,57 (figure 7 below). According to a report given by 
UNICEF in May 2018,3 the supply for IPV in 2018 will be enough to allow for the introduction or 
resupply of IPV in these 35 countries whilst sustaining supply in the high-risk countries.  
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Figure 7. Countries with IPV supply disruptions  
 
 
 
 
IPV= inactivated poliovirus vaccine, % = percent. The map was accessed from a presentation by Blanc D. C. and Ottosen A. 
about IPV supply.57 
Though there is hope for improved supply from 2018 going forwards, the amount will not be 
enough to meet the demand. In October 2017, SAGE recommended that every child that missed 
IPV doses since the switch from tOPV to bOPV should receive their missed doses.58 Therefore, in 
addition to sustaining supply for routine immunisation, the need for catch up immunisation 
campaigns is likely to increase demand. At the same time, a reserve for outbreaks should be in 
place to allow for quick response in affected areas. UNICEF estimates that the demand will be 
carried out beyond 2020.3 Post-certification, IPV will be the only vaccine being used for 
immunisation against polio.60 This impacts the current and future strategies for sustained IPV 
availability.   
The earliest improvement in supply is expected in 2021 when new vaccines achieve WHO 
prequalification status.3,59 From there on, excess capacity is expected to be in 2025.3,59 With few 
suppliers, options are limited. This creates unfavourable market conditions for IPV price decrease.3 
The prices for the next UNICEF tender period are set to be higher than those for the period 
between 2014 and 2018.3 A single full dose of IPV is expected to go for $3.50 in 2019 and will only 
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decrease to $2.80 in 2022.3 Improvement in the market conditions that allow for price reduction 
are expected in 2021 as new manufactures enter the market creating some competition.3,59 
4.  THE FUTURE OF POLIO 
4.1   Polio Eradication, Certification, and Integration Strategy 2019-2023 
2018 marked the end of the Polio Eradication and Endgame Strategy 2013-2018 and yet again the 
goal to eradicate polio remains elusive. According to a joint statement released by the leaders of 
the GEPI committees in January 2019, the Polio Eradication & Endgame Strategy 2013-2018 is now 
being revised and will extend up to 2023.61 The new strategy, the Polio eradication, certification 
and integration strategy 2019-2023, together with the Strategic action plan on polio transition62 
and the Polio post-certification strategy63, will outline the necessary steps to eradicate polio, 
transition from eradication to certification and to maintain a polio-free world post certification.62,63 
4.2  The future of IPV demand and supply 
IPV demand and supply forecast has been described above. As the world progresses towards global 
certification, eradication of both wild and vaccine derived poliovirus remains the main goal. IPV 
will still play an important role in the realisation of this goal. During the eradication phase, the use 
of IPV instead of OPV will be instrumental in reducing the number of cVDPV outbreaks. Considering 
the transition phase, GPEI will gradually decreasing its involvement while countries are taking up 
ownership of their polio programmes.62 Therefore, transitioning to independent country 
programmes will require adequate planning and availability of resources like IPV. To maintain a 
world-free of polio requires countries to use IPV only to mitigate the risk of cVDPV outbreaks.63 
Clearly, ensuring availability of IPV will continue to be part of the eradication, transition and post 
certification strategies.  
In 2007, the Advisory Committee on Poliomyelitis Eradication (ACPE) expressed the need to come 
up with “strategies for making IPV use potentially affordable for low income settings” before the 
cessation of OPV use.64 Since then, there has been research on schedule reduction,65 IPV antigen 
dose reduction (the use of a fraction of an IPV dose),66,67 adjuvant use68,69 and production of IPV 
from Sabin strains.68-71 The current shortages, bring us back to the same critical recommendation 
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that was made more than 10 years ago. These strategies need to be reconsidered in view of the 
current IPV shortages.  
5.  IS THERE A ROLE FOR FRACTIONAL-DOSE IPV? 
5.1  What is fractional-dose IPV? 
One fractional dose (0.1ml) is one fifth of the full dose (0.5 ml) and it is usually delivered using an 
intradermal injection.72 Compared to the subcutaneous or intramuscular routes of vaccine 
delivery, the abundant immune cells in the dermis of the skin allows for a lower amount of the 
vaccine to be used to invoke an immunologic response.56,73 Accordingly, using intradermal delivery 
of a fractional dose, it is possible to deliver 5 doses from the same volume of 1 full dose.  
The price of IPV affects the ability of countries to introduce and sustain supplies of IPV. GPEI’s 
target price for the universal use for IPV for a full dose is $0.50.9 In 2022, the price for a single full 
dose of is expected to be $2.803, which is far from the desired target. The cost of f-IPV is expected 
to be a fifth of the full dose9 therefore, as the market conditions become more favourable, reduced 
dosage might be quickest way to achieve the set target of $0.50. An assessment done by PATH 
showed that two f-IPV doses and the intradermal injection devices cost between US$1 to US$3 
while a single intramuscular dose of IPV costs between US$ 1.1 and US$2.3,56 As well, the 
assessment showed that the cost reduction from the reduced dosage can offset the cost of 
intradermal devices.56 
The dose sparing and cost reduction characteristics of f-IPV provide a compelling argument for the 
substitution of a full dose. For countries experiencing shortages, SAGE has recommended the use 
of two f-IPV instead of a full IPV dose in routine immunisation74,75 and the use of a single dose of 
f-IPV in outbreaks.76 WHO endorsed this recommendation in its position paper on polio vaccines 
and advised that the two doses are to be given at 6 and 14 weeks.6   
5.2  Considerations for adopting fractional-dose IPV in to national immunisation schedules. 
5.2.1  Immunological considerations 
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Levels and duration of seroprotection against paralytic disease is of paramount importance 
when considering adopting a f-IPV schedule. Several studies have compared the 
immunogenicity and effectiveness of f-IPV to a full dose IPV66,67,77,78 and a few reviews of 
literature have been done.79-81 Adding to the knowledge about the effectiveness of reducing 
the dose of IPV, this study gives a systematic analysis of the evidence which will assist in 
making decisions about IPV dosage. A detailed comparison of the available literature is given 
in section 6 below under study rationale. In terms of duration of immunity induced by f-IPV, 
there is lack of data in this area82,83 and more long-term research is required.  
The effectiveness of IPV to induce an immune response has been shown to be affected by 
the level of maternal polio antibodies within the vaccinated child.84,85 Interference of 
maternal antibodies has an impact on the age of administration of the IPV vaccine86 
therefore, it is a worthwhile consideration when deciding on a f-IPV vaccine schedule. 
Delaying immunisation to allow for maternal antibodies to decline results improves 
seroconversion.66,67 The challenge in delaying immunisation is that most developing 
countries use the EPI schedule with vaccination occurring at 6 weeks, 10 weeks and 14 weeks 
of age.86 At 6 weeks, maternal antibody are more likely to interfere but again this timing of 
administration is ideal because it allows for more children be vaccinated.63 Weighing risks 
and benefits is essential for choosing an appropriate schedule. GPEI encourages countries to 
access the drop-out rates between 6 and 14 weeks to make sure every child receives at least 
2 doses two doses.86  
Induction of intestinal mucosal immunity by IPV has been subject to debate for a long 
time.22,87 Having mucosal immunity during polio outbreaks is important because it prevents 
the replication of the polio virus within the intestines limiting person to person 
transmission.88 Brickley et al.89 suggests that without previous exposure to OPV, IPV does not 
improve intestinal mucosal immunity. This is consistent with other previous studies.90-93 In 
keeping with these studies, Jafari et al.94 and John et al.95 provided evidence that in children 
who have been previously immunised with OPV, a full dose of IPV boosts mucosal immunity. 
Gamage et al.96 compared the boosting of mucosal immunity by a single f-IPV versus a single 
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full dose of IPV in children aged 10-12 years who have been immunised with OPV. They 
showed that a f-IPV boosted mucosal immunity to a similar extent as a full dose IPV.96 Based 
on these results, f-IPV can be effectively used in outbreak response. This supports the 
decision made by SAGE to use f-IPV in outbreaks instead of a full dose.76 
5.2.2  Programmatic feasibility 
Vaccine administration 
A potential challenge in the use of f-IPV is the technical difficulty of intradermal vaccine 
delivery. The Mantoux technique, using a needle and syringe, requires technical expertise to 
ensure successful vaccine delivery whilst avoid vaccine wastage.82,97 Especially in campaign 
settings, where many children must be vaccinated in a short period of time, poor technique 
might result in inefficiency and ineffectiveness. Various alternative intradermal injection 
devices have been developed and registered56 (see table 3 below). Under trial and campaign 
conditions, some of these devices have been shown to give a similar or better immune 
response when compared to the standard needle and syringe.97-100 In this review, we will 
describe the intradermal devices used by investigators and where possible compare the 
immunological responses. Indeed, new injection devices provide easier options for 
intradermal vaccine delivery, however the cost of buying and training health workers on how 
to use the devices must be considered.  
Table 3. Devices for intradermal delivery of vaccines 
Device 
(supplier) 
Description Registered 
for use 
Tropis 
(PharmaJet) 
Needle-free jet injector that uses a sterile single-dose syringe 
and pressurized liquid stream instead of needle 
Yes 
MicronJet 600 
(NanoPass) 
Hollow microneedle hub that can be attached to a luer syringe 
following filling with a separate needle 
Yes 
ID Adapter 
(West 
Pharmaceutical 
Services) 
Plastic adapter that fits onto an autodisable intradermal needle 
and syringe that is provided with the device 
Yes 
Star ID Syringe 
(Star) 
 
Needle/syringe with a short minineedle and 90-degree injection 
angle, filled with an integrated plastic spike 
No 
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ID Pen (Bioject) Needle-free jet injector developed as an alternative to Bioject’s 
gas-powered Biojector2000 device that is optimized for 
intradermal administration in low-resource settings (manually 
powered, intradermal only) 
No 
Data in the table was extracted from table 1 in Okayasu et al.’s review on intradermal administration of 
fractional dose of IPV.56 
Another point to consider when looking at vaccine administration, is maintenance of the 
integrity of the vaccine vial stopper following repeated punctures. IPV is available in 1, 5 and 
10 standard dose vials therefore, giving fractional doses increases the number of piercings 
on the vial stopper which may eventually lead to vaccine leakage or contamination.101 
Jarrahian et al.101 examined vial stopper performance when using f-IPV. They concluded that 
after 50 punctures, less than 10% of the punctures resulted in particle formation and it was 
within the required target.101 In terms of vaccine leakage, Jarrahain and colleagues showed 
that 100 punctures did not lead to any closure failures.101 GPEI recommends the use of 1 and 
5 standard dose which give up to 5 and 25 doses respectively.86 The punctures required to 
withdraw f-IPV are way below the maximum punctures for contamination and leakage 
demonstrated by Jarrahain and colleagues. 
Health system considerations 
The process of implementing any policy within the health system is complex and 
interactive.101 It involves multiple actors at different levels of the health system, from the 
global level to the beneficiaries of the policy. Interactions between these people within the 
socio-political context of a country shapes the decision-making and implementation 
process103 of the f-IPV schedules in different countries. The WHO framework for health 
system strengthening104 is a tool that national steering committees can use as they consider 
the implementation of f-IPV schedules (see figure 8 below). 
Factors within each system building block must be assessed prior, during and after 
implementation to improve access and coverage of high quality and safe polio vaccination.104 
National leaders should be proactive and approve the adoption of the policy whilst ensuring 
that there is enough funding to cater for costs like vaccines, training, device purchasing and 
other logistics. In addition, the national regulatory authorities, after considering available 
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evidence86 and the use of fractional dosage in other vaccines,79,105,106 must deliberate on the 
approval of off-the label use of f-IPV. In view of providing high quality and broad vaccine 
coverage, frontline health workers form an integral part in the process of adopting f-IPV. 
They must be involved in the early stages of policy formulation so that they can contribute 
and play an active role in the implementation process. 
Figure 8. The WHO Health System Framework  
 
  
The framework was assessed from report by the WHO in 2007 entitled Everybody's business: strengthening health 
systems to improve health outcomes: WHO's framework for action.104 
The information building block highlights the importance of monitoring and evaluation in 
every step of the implementation process. Data collection for surveillance and information 
dissemination is the basis for evaluating the effects of the policy (including adverse effects). 
Hence, a plan on how to incorporate data on f-IPV into the national data registry is important. 
When considering service delivery, it is essential to look at how f-IPV will fit in with other 
vaccines in the national immunization schedule. This also includes cold chain management 
and availability of transportation and vaccinators.  
Communication amongst global actors (WHO, UNICEF, GPEI and GAVI), national level actors 
(Presidents and health ministers) and provincial and frontline workers at different stages of 
policy development is of uttermost importance. This requires constant dialogue and 
feedback amongst all parties involved in an environment of mutual respect. Beneficiaries of 
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the policy (children, parents and community leaders) should be informed and educated 
about the benefits of f-IPV and immunisation in general. This cultivates an environment for 
the policy to be accepted by the community. 
5.3  Experiences of fractional-dose IPV in other countries 
5.3.1  Use of fractional-dose IPV in routine immunisation 
This dose sparing strategy might be the immediate solution the world needs to ensure that 
every child who is entitled to get IPV gets vaccinated. From the WHO South-East Asia Region, 
India, Sri Lanka, Bangladesh and Nepal have decided to adopt f-IPV in their national routine 
immunisation schedules.88,107 India has been the front runner amongst these countries. In 
April 2016, India introduced two f-IPV doses at 6 and 14 weeks in the routine immunisation 
schedule of 8 states then another 8 states were added in August 2016.72 They managed to 
embark on a nationwide scale up in March 2017. Sri Lanka followed in July 2016, using the 2- 
and 4-months schedule.72 In both countries, they have managed to immunise a larger 
number of eligible children, stretching their stocks and avoiding stock outs.51,56 Bangladesh 
and Nepal were expected to shift to fractional dosage in the last quarter of 2017 and first 
quarter of 2018 respectively.107 
Other WHO regions are now starting to discuss and setting up structures that enable the use 
of f-IPV. In the Americas, PAHO has recommended the use of f-IPV in 14 countries. Some of 
the countries are already conducting trainings in preparation for implementation.107 WHO 
Eastern Mediterranean region and African region are also deliberating on the use of f-IPV.107  
5.3.2  Use of fractional-dose IPV in campaigns 
Supplementary immunisation activities using f-IPV have been successfully carried out in India 
and Pakistan. In response to a VDPV type 2 isolate that was found in Telangana State of India 
in May 2016, a mass vaccination campaign using a single f-IPV dose was successfully carried 
out.108 The campaign was carried over 6 days and 311 064 children aged between 6 weeks 
and 3 months were vaccinated achieving a coverage of about 94 %.107 In Pakistan, a mass 
vaccination campaign using a single dose of f-IPV was carried in the province of Hyderabad 
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and 3 other surrounding provinces in August 2016.109 This was after a VDPV type 2 isolate 
was isolated from a sewage sample. Through the campaign a coverage of about 82% was 
achieved.108 Challenges encountered in the campaign in Pakistan included the difficulty of 
intradermal delivery in an outbreak setting. However, Yousafzai et al.97 and Saleem et al.98 
have shown the effectiveness of intradermal devices in door to door campaign and one-day 
campaign. 
6.  STUDY RATIONALE 
As mentioned above, the immunogenicity and effectiveness of f-IPV are important considerations for 
countries that want to adopt f-IPV into their schedules. Advantages of evidence-based policy making 
have been elaborated.110 Providing evidence about the effectiveness of f-IPV bridges the gap between 
research and policy adoption and implementation. This study adds to the body of knowledge that guides 
the use of f-IPV in the prevention of polio.  
Recognizing the high cost of IPV and the imminent cessation of OPV use, Nelson et al.79 performed a 
literature review in 2012 to describe available studies that used intradermal delivery of IPV. The authors 
concluded that intradermal delivery of IPV was a viable mechanism for cost reduction.79 They also 
highlighted the need to consider the effect of maternal antibodies, duration of immunity and use of 
adjuvants.79 In contrast to Nelson et al.’s79 narrative description of included studies, Grassly80 carried out 
a systematic review and metanalysis to assess the immunogenicity and effectiveness of 1 or 2 doses of 
IPV. Grassly80 broadly outlined and compared the existing IPV dosage options. Concerning f-IPV, the 
author established that the immunogenicity of 2 doses of f-IPV is comparable to a single full dose, but 
the antibody titres were lower. This finding is similar to what Anand et al., 81 found in their literature 
review in 2017. Anand and colleagues (2017) only focused on studies that compared the immunogenicity 
of one full-dose of intramuscular IPV to two doses of intradermal f-IPV.81 From their review, they 
established that two f-IPV doses are more immunogenic than a single full-dose.  
All the authors used a narrow search strategy and they also searched for relevant studies in a limited 
number of sites. Nelson et al.79 searched in PubMed and some chapters in Plotkin’s Definitive Vaccine 
Textbook while Grassly80 only searched the Web of Knowledge database. Anand et al.81 performed their 
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search in PubMed only. Due to the absence of an extensive search for literature, there might be other 
studies that were excluded from these reviews that may alter their findings. In addition to a restricted 
search, Grassly’s (2014) study selection and data extraction were not done in duplicate;80 increasing the 
risk of systematic errors.111 It is an indispensable practice in systematic reviews to conduct those steps 
in duplicate and resolve discrepancies by discussion and consensus or arbitration.111 
In addition to effectiveness, vaccine safety and administration is of importance when deciding to adopt 
any vaccine. Showing that a vaccine is safe and effective promotes acceptability amongst health workers 
and the community at large. In the three reviews, there is dearth of information about the adverse 
effects and the devices used for intradermal injections.  
None of the previous reviews used the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) method112 to assess the certainty of the evidence on effects of f-IPV. This approach 
assesses the certainty of a body of evidence through evaluating the risk of bias, imprecision, 
inconsistency and indirectness of study results, and the risk of publication bias.113,114 The level of 
certainty of evidence, is useful when providing evidence for policy making. 
In view of the gaps identified in previous reviews, the purpose of this review is to do a systematic review 
of studies comparing the effects of fractional compared to full dose IPV vaccination. We will also, 
evaluate the occurrence of adverse events and types of administration devices used for the intradermal 
delivery of f-IPV. The review will have a broader search strategy and provide up to date evidence 
regarding the use of f-IPV. This will provide evidence to support the use of f-IPV in routine immunisation 
because of its dose sparing and cost reduction characteristics. 
7.  SUMMARY 
It has been 31 years since the WHA decided to globally eradicate polio.30 Learning from the successes of 
small pox eradication and eradication of polio in the Americas, GPEI and its partners, has successfully 
decreased the burden of polio worldwide. By so doing, they have averted polio deaths and saved the 
world millions of dollars. The Polio Eradication and Endgame Strategy 2013-2018 has brought us to the 
brink of eradication. Going forward, the Polio eradication, certification and integration strategy 2019-
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2023, the Strategic action plan on polio transition and the Polio post-certification strategy will hopefully 
lead to the global certification of polio eradication.  
 In the remaining endemic countries, multiple social, political and economic factors affect polio 
eradication therefore, a multi-pronged approach is required to eradicate polio and tackle cVDPV 
outbreaks globally. One of the approaches is to replace OPV with IPV. Phased replacement of OPV by IPV 
has been initiated through the switch from tOPV to bOPV and the addition of at least 1 dose of IPV in all 
immunisation schedules. Progress in the phased removal has been affected by global shortages of IPV 
which resulted from increased demand and low supply. This delays the interruption of VDPVs and at an 
individual level, many children are being denied their right to access effective vaccines.  
Fractional-dose IPV clearly has role to play in the journey towards eradicating polio. Administering 
reduced doses of IPV will stretch supplies of IPV whilst ensuring that every child receives their vaccine. 
Its dose sparing, and cost reduction properties can improve vaccine availability and affordability. 
Immunological and programmatic factors are important when deciding on national IPV immunisation 
schedules. The aim of this study is to provide immunological as well as vaccine safety and administration 
evidence to assist in decision making regarding IPV dosage.  
8.  RECOMMENDATIONS  
8.1  Research 
• More studies should focus on investigating the duration of immunity induced by f-IPV when 
compared to the full dose of IPV. This information will aid in determining an effective f-IPV 
schedule and whether booster immunisation is required. 
• The importance of mucosal immunity has been highlighted above. Additional studies should be 
carried out to solidify the finding by Gamage et al.92 (f-IPV boosts mucosal immunity to the same 
extent as a full dose of IPV). 
8.2  Policy implementation 
• Global partners and governments should engage manufactures of IPV to facilitate the mass 
production of IPV that will bridge the demand-supply gap 
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• Global partners and governments should engage manufactures of IPV to facilitate licensure of 
fractional-dose of IPV. 
• National health committees in low-income regions should start discussing the possibility of taking 
up fractional-dose of IPV based on evidence from other regions like the WHO South-East Asia 
Region. 
• Before the transition phase, financial and resource (including vaccine) availability should be 
considered. There is a risk of losing the eradication gains that have been achieved in the past 30 
years if  national governments fail to sustain their programmes. 
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SUMMARY 
Background 
Following the recommendation by WHO to introduce at least a single dose of inactivated poliovirus 
vaccine (IPV) in routine immunisation schedules, there has been global IPV shortages. Fractional-dose 
IPV is one of the strategies to ensure IPV availability. We did a systematic review of studies comparing 
the effects of fractional compared to full dose IPV vaccination.  
Method  
For this systematic review and metanalysis, we searched for articles in 16 databases. The sites were 
searched from inception to the 11th of April 2018 with no date, language or publication restrictions. We 
included studies which compared fractional-dose to full-dose IPV in children aged 5 years or younger 
regardless of study design, number of doses and route of administration. Screening, selection of studies, 
data extraction and risk of bias assessment was done in duplicate. Differences in judgement between 
the two authors were resolved by discussion and consensus or arbitration by a third author. The main 
outcome of interest was immunogenicity which was assessed using seroconversion rates and geometric 
median titres. In studies with similar characteristics, estimates were pooled using a random-effects 
model. Heterogeneity was assessed using χ2 test of homogeneity and quantified using the I2 statistic. 
Analysis was stratified by type of outcome measure, type of poliovirus, and number of IPV doses given. 
Subgroup analysis and sensitivity analysis were carried out. Analysis was done using Rev Man 5.3. 
PROSPERO registration number: CRD42018092647. 
Findings 
We identified 858 non-duplicate records, of which 35 potentially eligible full-text articles were screened 
and 17 articles included. Of the 17 articles, 3 are records of on-going trials and the remaining 14 articles 
are publications of eight studies. For poliovirus type 2, seroconversion risk ratio (RR) at 3 doses was 0.95 
(95% CI 0.91, 1.00; p=0.06) at 2 doses 0.87 (0.71, 1.05; p=0.14) and at 1 dose 0.61 (0.50, 0.73; p<0.00001). 
The standard mean difference (SMD) for poliovirus type 2 at 3 doses was -0.98 (95% CI -1.46, -0.51; 
p<0.0001), at 2 doses -0.55 (-0.80, -0.30; p<0.0001) and at 1 dose was -0.53 (-0.90, -0.15; p=0.006). The 
seroconversion meta-analysis for 3-dose comparison was homogenous (χ2 p=0.45; I2=0%) while 
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heterogeneity was observed in the 2-dose comparison (χ2 p<0.00001; I2=93%) and 1-dose comparison 
(χ2 p=0.0002; I2=77%). Immunisation schedules with a longer interval between birth and timing of first 
dose and between 2 doses were associated with increased immunogenicity. The certainty of the results 
for the 3-dose comparison was high. 
Interpretation 
There is no difference in seroconversion between 3 doses of f-IPV (0.1ml) and 3 doses of full dose IPV 
(0.5ml) even though the full dose gives higher anti-polio type 1, 2 and 3 titres. With the current IPV 
shortages, using f-IPV instead of the full dose IPV can stretch supplies.  
Funding 
South African Medical Research Council and the National Research Foundation of South Africa 
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1.  INTRODUCTION 
The World Health Assembly (WHA) in 1988 committed to globally eradicate poliomyelitis (polio).1 Since 
then, the incidence of polio has reduced to less than 1% globally; Nigeria, Afghanistan and Pakistan are 
the only countries that still have endemic polio; and of the 3 wild polioviruses, type 2  has been 
eradicated while type 3 was last seen in November 2012 in Nigeria.2 Vaccination against polio using the 
oral poliovirus vaccine (OPV) has played a major role in achieving these successes. However, the 
association of OPV with vaccine derived polioviruses (VDPVs) and vaccine derived paralytic poliomyelitis 
(VAPP)3 has paved a way for inactivated poliovirus vaccine (IPV) to be the vaccine of choice in this final 
phase of eradicating polio. 
In April 2016, the global switch from trivalent OPV (tOPV) to bivalent OPV (bOPV) marked the first step 
towards the phased removal of OPV.4 Prior to switching, the World Health Organisation (WHO)  and the 
Strategic Advisory Group of Experts (SAGE) on immunisation recommended that countries should 
introduce at least 1 dose of IPV in their schedules.5,6 Following the recommendation, the demand for IPV 
has increased while the supply has deteriorated.7 This has led to delayed IPV introduction and resupply7 
while at the same time affecting global reserves for outbreaks.8 The increase in demand is expected to 
stretch up to 2020 while supplies are expected to surpass demand by 2025.7  
Fractional-dose IPV (f-IPV) is one of the strategies being used to address the IPV shortages.8 The reduced 
dose which is usually given intradermally, is one fifth (0.1ml) of the full dose(0.5ml) and  is expected to 
cost less than the full dose.9 Due to its  dose sparing and cost reduction characteristics, countries like 
India and Sri Lanka have opted to use f-IPV in their routine immunisation schedules instead of the full 
dose.10 In addition, India and Pakistan have used f-IPV in outbreak situations.10  
A few reviews have investigated the effects of f-IPV dose(s) compared to full dose(s) of IPV.11-13 Of note, 
in these reviews there is an absence of extensive search for literature therefore, there might be other 
studies that were excluded that may alter their findings. Furthermore, none of these reviews 
investigated adverse events and vaccine administration which are important factors when deciding on a 
national vaccine schedule. In one of the systematic reviews the procedures were performed by one 
person.12 This increases the risk of introducing bias in the process of reviewing literature.14 After analysis, 
none of the authors used the Grading of Recommendations Assessment, Development and Evaluation 
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(GRADE) approach15 to assess the certainty of their results. This approach guides evidence users in 
deciding on whether to adopt an intervention. 
We performed a systematic review of studies comparing the effects of fractional to full dose(s) of IPV 
vaccination. We also evaluated the occurrence of adverse events and types of administration devices 
used for the intradermal delivery of f-IPV.   
2.  RESEARCH IN CONTEXT 
2.1  Evidence before this study 
To identify systematic or literature reviews that have compared f-IPV dose(s) to full dose(s) of IPV, 
we used the search strategy in appendix A table 1.  From the search we found 2 literature reviews 
and 1 systematic review that were related to either reduced dose or intradermal delivery (ID) of 
IPV.  Important gaps that were identified include: narrow search strategies, lack of assessment of 
certainty of results and absence of data concerning adverse events and vaccine administration. 
These factors reduce the reliability of results obtained from these reviews. 
2.2  Added value of this study 
In addition to looking at effectiveness of f-IPV dose(s) versus full-dose(s) IPV, in our systematic 
review, we compared the incidence of adverse events, wild poliovirus poliomyelitis and vaccine 
derived paralytic poliomyelitis in both arms. We also evaluated types of administration devices 
used for the intradermal delivery of f-IPV. To ensure that we capture all the relevant literature, we 
used a broad search strategy and searched for both peer-reviewed and grey literature in 16 
databases. After data analysis, we used the GRADE approach to assess the certainty of our findings.  
2.3  Implications of all the available evidence 
Our review findings strengthened the existing evidence from previous reviews. We performed a 
same dose analysis including a comparison after 3 doses of either f-IPV or full dose IPV. In addition, 
we assessed the adverse events, the occurrence of wild poliovirus poliomyelitis and vaccine 
derived paralytic poliomyelitis (VAPP), mucosal immunity and intradermal devices used to deliver 
f-IPV. Together this evidence will advise immunisation policy makers and other key evidence users 
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on the f-IPV dosing and the adoption of f-IPV into national immunisation schedules. To further 
assist evidence users, we analysed the certainty of our results using the GRADE approach. 
3.  METHODS 
3.1  Search strategy and selection criteria 
In this systematic review and meta-analysis, using keywords and MeSH terms (appendix A table 1) 
developed in PubMed and adapted for other databases, we searched for peer-reviewed and grey 
literature from the 16 databases outlined in appendix A table 2. The databases were searched from 
inception to the 11th of April 2018 with no date, language or publication restrictions. 1 article16 
was translated before eligibility assessment. Trial registries (appendix A table 2) were searched for 
relevant completed and on-going studies. Additionally, we searched the WHO and Global Polio 
Eradication Initiative (GPEI) websites and reference lists of included studies, related reviews, and 
relevant WHO vaccine position papers.  
We included studies which compared fractional-dose(s) to full-dose(s) IPV in children aged 5 years 
or younger regardless of study design, number of doses and route of administration. Studies were 
IPV was given in combination with OPV were also included. Summary estimates were extracted for 
comparison. Thandiwe Mashunye and Kopano Dube independently assessed eligibility and 
extracted data from included studies. Any disagreements between the two authors regarding 
study eligibility and data extraction were resolved by discussion and consensus. A third author, 
Duduzile Ndwandwe or Charles Wiysonge, adjudicated any unresolved disagreements. Were 
necessary, authors were contacted to obtain additional information or resolve disputes.  
3.2  Data analysis 
Study characteristics were extracted independently by Thandiwe Mashunye and Kopano Dube 
using a piloted data extraction form (appendix C). In studies with multiple study arms, only data 
from arms relevant to the review was extracted. Our main outcome of interest was 
immunogenicity. Specific measures for immunogenicity that were used were proportion of 
participants who seroconverted and changes in titres of anti-polio type 1, 2 and 3. Secondary 
outcomes analysed were the occurrence of adverse events; wild poliovirus poliomyelitis; vaccine 
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derived paralytic poliomyelitis and the development of mucosal immunity. We also described the 
routes and devices used for f-IPV vaccination. 
To determine the quality of studies, the Cochrane Risk of Bias tool for trials17 was used 
independently by Thandiwe Mashunye and Kopano Dube.  6 of the tool’s 7 domains for assessing 
bias were used. Blinding of personnel and participants (performance bias) domain was excluded 
because of the challenge of blinding when different routes of vaccine administration, intradermal 
versus intramuscular, are used to vaccinate participants. Each study was classified into low, high 
and unclear risk and RevMan 5.318 was used to create a risk of bias table (table 4). Judgements for 
level of risk are outlined in appendix A table 5. Differences in judgements were resolved by 
discussion and consensus, or arbitration by a third author Duduzile Ndwandwe or Charles 
Wiysonge.  
We used risk ratios (RR) and corresponding 95% confidence intervals to summarise seroconversion 
proportions, adverse events, mucosal immunity and the incidence of wild poliovirus poliomyelitis 
and vaccine derived paralytic poliomyelitis. The standardised mean difference (SMD) and its 95% 
confidence interval was used to summarise anti-polio 1, 2 and 3 titres. For studies with similar 
participants, interventions, outcomes, and study designs, we pooled the study data using the 
random-effect method of meta-analysis. Only studies comparing the same number of doses of 
fractional versus full doses of IPV were compared. Analysis was stratified by type of outcome 
measure, type of poliovirus, and number of IPV doses given. For all outcomes, the total number of 
participants that were randomised at the beginning of the study were used to analyse data. Drop 
outs were regarded as failures. To avoid double counts, multiple arms were combined. We 
assessed for statistical heterogeneity by visually inspecting forest plots and using the χ2 test of 
homogeneity;17 with significance defined at the alpha level of 0.10. The I2 statistic17 was used to 
quantify the amount of heterogeneity. To investigate heterogeneity, we performed subgroup 
analysis using the following classifications: timing of first dose, interval between doses, age of 
administration, number of fractional doses, poliovirus type (1, 2 and 3), type of intradermal 
injection device, immunisation schedules, and country income status. We performed sensitivity 
analysis based on level of bias, methods of metanalysis and by considering missing data as either 
successes or failures. 
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The GRADE approach15 was used to evaluate the certainty of evidence and the results were 
summarised using a GRADE summary of findings table. Studies that were assigned a high risk for 
allocation concealment, blinding of outcome assessment, or completeness of outcome were 
considered to have a high risk of bias. Differential losses to follow-up of more than 10% between 
fractional and full dose groups was considered as high risk.  
Statistical analysis was performed using RevMan 5.3.18 This systematic review and metanalysis was 
reported in accordance to the PRISMA guidelines19 (appendix C). The review was registered under 
PROSPERO International Prospective Register of Systematic Review (registration number: 
CRD42018092647). 
4.  ROLE OF FUNDING 
The funder of the study had no role in study design, data collection, data analysis, data interpretation, 
or writing of the report. The data were available to all authors on request. The corresponding author had 
full access to all the data in the study and had final responsibility for the decision to submit for 
publication. 
5.  RESULTS 
1207 citations were identified through a systematic database search and 113 additional citations were 
identified from grey literature (figure 1, appendix A table 2). 482 duplicate citations were removed and 
the titles and abstracts of the remaining 858 citations were screened using the inclusion and exclusion 
criteria. 35 citations were eligible for full text review. From the 17 articles included after full-text review, 
3 on-going trials were excluded, and 8 studies published in 14 articles were included in the meta-
analysis.20-33 We excluded 12 studies which assessed the effect of reduced antigen doses using Sabin 
derived IPV (table 3). 5 studies were participants were given f-IPV without the comparative full dose IPV 
were also excluded (table 3). 
Of the 8 studies included in the meta-analysis (table 1), 3 studies took place in Cuba and the other studies 
were done in Oman, Philippines, India, Bangladesh and the Gambia. All 8 studies were randomised 
controlled trials published between 2010 and 2016. Studies done between 2010 and 2013 focused on 
comparing the immunogenicity of f-IPV and the full dose IPV20-22,25,26 whilst the last 2 studies published 
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in 2015 and 201629,31 focused on assessing the quality and efficiency of using different intradermal 
devices for f-IPV administration. Study participants were below 12 months of age except in 1 study29 
were participants were aged between 12 to 20 months. In all studies, the intervention and control groups 
received an equal number of IPV doses. 3 studies had a 3-dose schedule,20-22 2 studies had a 2-dose 
schedule26,27, and in 3 studies25,29,31 participants received a single dose.  In all the single dose studies, 
participants were exposed to OPV before study vaccines as part of routine or supplementary 
immunisation. The outcome assessment for the studies were similar except for 1 study28 which used the 
Salk based assay which is more sensitive than the Sabin based assay. Table 1 shows characteristics of 
studies included in the meta-analysis and table 2 shows characteristics of on-going trials. 
For poliovirus type 2, the proportion of those who seroconverted after f-IPV vaccination increased as the 
number of IPV doses increased such that at 3 doses the proportion approximates the proportion that 
seroconverted after 3 full doses of IPV (figure 2). The risk ratio (RR) at 1 dose was 0.61 (95% confidence 
interval (CI) 0.50, 0.73; p<0.00001), at 2 doses 0.87 (0.71, 1.05; p=0.14) and at 3 doses 0.95 (0.91, 1.00; 
p=0.06). This result corresponds to what was observed for poliovirus type 1 and type 3 (appendix B figure 
1 and 2) though some of the plots favour the full dose. For all dose schedules, participants vaccinated 
with full dose IPV had higher anti-polio 1, 2 and 3 titres than those vaccinated with f-IPV.  The 
standardised mean difference (SMD) between the mean antibody titres increased as the number of IPV 
doses increased (figure 3). The SMD for poliovirus type 2 at 1 dose was -0.53 (95% CI -0.90, -0.15; 
p=0.006), 2 doses -0.55 (-0.80, -0.30; p<0.0001) and 3 doses -0.98 (-1.46, -0.51; p<0.0001). The trend was 
similar for poliovirus type 1 and type 3 (appendix B figure 3 and 4). 
Severe adverse events were reported in 2 studies.21,27 The events are described in appendix B table 1. 
Compared to the full dose arm, severe adverse events occurred less frequently in the f-IPV arm. The RR 
was 0.76 (95% CI 0.44, 1.32; p=0.32). Local injection site adverse events occurred more frequently in the 
f-IPV arm: pain/tenderness RR 1.20 (95% CI 0.95, 1.51; p=0.12), redness/erythema 4.10 (1.52, 11.11; 
p=0.005) and swelling/induration 4.96 (2.26, 9.74; p<0.0001). 7 systemic adverse events were analysed. 
2 occurred more frequently in the full dose arm compared to the f-IPV arm: fever RR 0.71 (95% CI 0.58, 
0.86; p=0.0006) and loss of appetite 0.81 (0.51, 1.27; p=0.36). 2 occurred more frequently in the f-IPV 
arm: vomiting RR 1.11 (95% CI 0.46, 2.71; p=0.81) and irritability 1.14 (0.86, 1.50; p=0.36). The 
occurrence of 3 systemic event was almost equal in both arms: drowsiness RR 1.07 (95% CI 0.76, 1.51; 
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p=0.68), excessive crying 0.93 (0.56, 1.55; p=0.78) and diarrhoea 1.03 (0.71, 1.74; p=0.88). Analysis of 
adverse events is shown in appendix B figure 5. 
1 study25 reported the occurrence of wild poliovirus type 3 infection in a single participant who had 
received a single full dose of IPV after receiving tOPV in routine immunisation and supplementary 
monovalent OPV type 1 (mOPV1). VAPP cases were not reported in any of the studies.  
The intradermal vaccine delivery route was used for f-IPV vaccination in all included studies. 6 included 
studies20-22,25-27 used a single intradermal device to vaccinate participants with f-IPV. Jet injection was 
used in 4 of the studies. 3 studies20,21,26 used the Biojector 2000 (Bioject) whilst 1 study25 used the Tropis 
(PharmaJet). 2 of the 6 studies that used a single intradermal device delivered f-IPV using microinjection 
and the Mantoux method.22,27 The study that used microinjection used the Micronjet 600 (Nanopass)27 
and the one that used the Mantoux method used a needle and syringe.22 2 included studies used more 
than a single intradermal device to administer f-IPV.29,31 In 1 study29 4 devices were used: BCG needle 
and syringe; Biojector 2000 (Bioject); Tropis (PharmaJet); and an intradermal pen injector (Bioject). The 
other study31 used 2 devices: Tropis (PharmaJet) and a needle and syringe.   
Mucosal immunity was investigated in 2 included studies21,27 In 1 study21 poliovirus shedding in stool was 
measured at 7 months, 1week after the participants were challenged with mOVP1 following 3 doses of 
either f-IPV or full dose IPV. VDPV type 2 shedding was detected in a single participant for each arm.  1 
participant in the f-IPV arm had VDPV type 3 shedding while in the full dose IPV arm VDPV type 3 
shedding was not detected. There was more VDPV type 1 shedding in the f-IPV compared to full dose 
IPV (RR 1.17; 95% CI 0.98, 1.41; p=0.09, appendix B figure 13). In the other study,27 poliovirus shedding 
in stool was measured at 18weeks, 1week after the participants were challenged with tOPV following 2 
doses of either f-IPV or full dose IPV. Amongst those who got f-IPV, one arm was given a single dose of 
bOPV at 10 weeks. Those who received the full dose had more VDPV type 1 and 2 shedding compared 
to the f-IPV/bOPV arm (VDPV type 1 RR 0.27; 95% CI 0.19, 0.40; p<0.00001 and VDPV type 3 RR 0.43; 
95% CI 0.29, 0.66; p<0.0001, appendix B figure 14). In the f-IPV only arm there was more VDPV type 2 
and 3 shedding compared to the full dose arm (VDPV type 2 RR 1.10; 95% CI 0.91, 1.32; p=0.32 and VDPV 
type 3 RR 1.26; 95% CI 0.94, 1.71; p=0.12, appendix B figure 13). 
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Visual inspection of the forest plots in figure 3 suggests heterogeneity in the plots for 2 and 1 dose 
comparisons of poliovirus type 2 seroconversion. In both plots, the I2 statistic and chi-squared test for 
homogeneity confirmed the heterogeneity (2 dose comparison: χ2 p<0.00001; I2=93% and 1 dose 
comparison: χ2 p=0.0002; I2=77%, figure 3). The seroconversion meta-analysis for 3-dose comparison 
was homogenous (χ2 p=0.45; I2=0%). Subgroup analysis showed that poliovirus type 2 seroconversion 
was dependent on timing of first dose, interval between doses and immunisation schedule. Regardless 
of number of doses given, as the period between birth and timing of the first dose increased the RR 
moved much closer to the null (appendix B figure 6). For the 2-dose comparison, when the first dose was 
given at 6 weeks RR was 0.83 (95% CI 0.75, 0.92; p=0.004), at 2 months 0.82 (0.73, 0.92; p=0.78) and at 
4 months 1.01 (0.96, 1.05; p=0.001). As the interval between 2 doses increased the RR moved closer to 
the null (appendix B figure 7). For the 2-dose comparison, a schedule with a 4-week interval had an RR 
of 0.77 (95% CI 0.64, 0.93; p=0.005), a 2-month interval 0.84 (0.78, 0.91; p<0.0001) and a 4-month 
interval 1.01 (0.96, 1.05; p=0.001). Immunisation schedules whose timing of the first dose was the 
furthest away from birth and whose 2-dose interval was the furthest apart, the RR was closer to the null 
(figure 4). For the 2-dose comparison, a 6wks and 10wks schedule had an RR of 0.77 (95% CI 0.64, 0.93; 
p=0.005), a 6wks and 14wks schedule 0.86 (0.77, 0.95; p=0.004), a 2 months and 4 months schedule 0.82 
(0.73-0.92; p=0.001) and a 4 months and 8 months schedule 1.01 (0.96, 1.05; p=0.001).  
Results after stratifying by country status and intradermal devices depended on the immunisation 
schedules used in the studies therefore, the results were not reliable (appendix B figure 8 and 9). 
Consequently, subgroup analysis for intradermal devices was done using 1-dose comparisons at the 
same age of administration.  In the study that used the Tropis (PharmaJet) and a needle and syringe for 
f-IPV administration as a single dose at 10-12 months,31 the RR when a needle and syringe was used was 
nearer to the null when compared to the RR when the Tropis (PharmaJet) was used (appendix B figure 
11). For poliovirus type 1, the RR for the needle and syringe was 0.83 (95% CI 0.70, 0.99; p=0.04), and 
the RR for Tropis (PharmaJet) was 0.65 (95% CI 0.53, 0.79; p<0.0001. In the study that used 4 intradermal 
devices,29 Tropis (PharmaJet) RR was nearest to the null followed by BCG needle and syringe and the 
Biojector 2000 (Bioject) (appendix B figure 12). The intradermal pen injector was the least successful 
device (appendix B figure 12). RR for Tropis (PharmaJet) was 0.60 (95% CI 0.46, 0.79; p=0.0002), Biojector 
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2000 (Bioject) 0.56 (0.48, 0.66; p<0.00001), BCG needle and syringe 0.55 (0.40, 0.75; p=0.0002) and 
intradermal pen injector (Bioject) 0.45 (0.32, 0.63; p<0.00001). 
In general, all studies were low risk studies. Data for randomisation and allocation concealment in 5 
studies20-22,27,29 was either missing or not adequately described to make a judgement (table 4). Two 
studies had missing data amounting to 23%20 and 13%25 respectively. Since the differential loss to follow 
up between the review comparison groups was less than 10% (5%20 and 7%25) both studies were 
assigned a low risk of attrition bias. All the studies had a low risk of detection bias, reporting bias and 
having any other biases (table 4).  
We performed sensitivity analysis were missing data was regarded as success or failures. The difference 
in the results using either participants who completed the study or participates who were randomised 
at the beginning of the study was negligible (appendix B figure 15-18). Especially for poliovirus type 2 
and type 3, effects obtained using the fixed effects model were nearer to the null when compared to 
effects obtained using the random effects model (appendix B figure 18-20).  
Using the GRADE approach (table 5), the certainty of evidence for poliovirus type 2 seroconversion at 3 
dose comparison (RR 0.95; 95% CI 0.91, 1.00; p=0.06) was high. For the 2-dose comparison (RR 0.87; 95% 
CI 0.71, 1.05; p=0.14) was low and for the 1 dose comparison (RR 0.61; 95% CI 0.50, 0.73; p<0.00001) it 
was moderate. The levels were similar for poliovirus 1 and 3. 
All the analysis is available under appendix B 
6.  DISCUSSION 
Our results suggest that there is no difference in seroconversion between 3 doses of f-IPV and 3 dose of 
full dose IPV even though the full dose gives higher anti-polio type 1, 2 and 3 titres. As the number of 
doses increases the seroconversion rates for f-IPV and full dose IPV approximate each other. An 
immunisation schedule which has a longer interval between birth and timing of first dose and between 
two successive doses is more likely to improve the seroconversion potential following 3 doses of f-IPV. 
Our results strengthen and adds to the evidence of previous reviews.11-13 These reviews showed that 
two doses of f-IPV were more immunogenic than 1 full dose of IPV and delaying timing of first dose and 
increasing interval between doses increased the immunogenicity of f-IPV.12,13 This review added to this 
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evidence by performing same dose comparisons at 1, 2 and 3 doses of IPV. 1 of our included studies22 
used a Salk based assay to measure antibody titres which is more sensitive than the Sabin based assay. 
This could have pulled our results of the 3-dose comparison nearer to the null.  
IPV supply is falling behind the increasing demand for the vaccine.7 Our result show that f-IPV is a viable 
alternative to using full dose IPV. From 1 full dose of IPV it is possible to administer 5 f-IPV doses. 
Accordingly, f-IPV can stretch supplies offsetting the demand-supply gap. In countries, using the bOPV 
and 1 full dose IPV schedule, that are facing IPV shortages, WHO recommends the use 2 f-IPV doses given 
at 6 and 14 weeks instead of the full dose.6 Our results push this recommendation further by proposing 
the replacement of bOPV with f-IPV. This even applies to countries who use the full dose IPV only 
schedules. These countries can conserve resources by using f-IPV. One of the polio eradication strategies 
is the phased replacement of OPV by IPV.34 Some of the considerations for replacing OPV with f-IPV are 
discussed below. 
Immunological considerations include the effect of maternal antibodies, mucosal immunity and duration 
of immunity. Maternal antibodies against polio interfere with the successful immunisation of a 
vaccinated child,35 therefore, delaying timing of the first dose gives enough time for the maternal 
antibodies to wane off.12,13,26 This affects polio immunisation schedules. Two commonly used polio 
immunisation schedules are the 6-, 10-, and 14-week schedule and the 2-, 4- and 6-month schedule.36 
From our review findings, the 2-,4- and 6-month schedule is more ideal for f-IPV vaccination. This creates 
a challenge for many low-income countries which use the 6-, 10- and 14-week schedule with a low 
dropout rate.36 In such countries, it is worthwhile to weigh the benefits of delaying and increasing the 
dose intervals for f-IPV vaccination and the cost of children missing vaccination opportunities. Mucosal 
immunity after IPV vaccination has been subject to debate.38 It has been suggested that without prior 
exposure to OPV, IPV does not improve intestinal immunity.39 A study that compared mucosal immunity  
after  ether a single dose of f-IPV or a full dose IPV in 10 year olds who had been exposed to OPV showed 
no difference between using either of vaccines.40 In one of our studies,27 the arm were f-IPV was given 
sequentially with OPV had less virus shedding than the arm given  f-IPV only. The study where mucosal 
immunity was measured after ether 3 doses of f-IPV or 3 full doses of IPV21 suggested that more doses 
can potentially reduce polio virus shedding. OPV promotes mucosal immunity therefore the risk of 
reduced mucosal immunity must be weighed against the benefits of replacing OPV with f-IPV. Looking 
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at duration of f-IPV immunity, a study that compared the booster dose of f-IPV and full dose after a 3-
dose primary schedule showed comparable immunogenicity.22 As up take of f-IPV increases, research on 
duration of immunity and booster vaccination is required. 
Providing evidence for vaccine safety increases uptake. f-IPV is safe to administer to children. The 
incidence of the adverse events that we investigated was low in both comparison groups. Most of the 
severe adverse events were all hospitalisations that occurred after study vaccination. It is possible that 
these hospitalisations were not related to the study vaccine since young infants are susceptible to 
infection because of a weak immune system. Local injection adverse events are to be expected following 
f-IPV vaccination because of method and devices used to deliver the vaccine. One of the reasons why 
IPV is an ideal replacement for OPV is that it is not associated with VDPVs. In our review, VAPP was not 
detected in any of the studies. This reinforces the need for scaling up the replacement of OPV with IPV.  
Using a the Mantoux method to administer f-IPV intradermally, affects the effectiveness and efficiency 
of wide scale f-IPV vaccination. Alternative intradermal devices have been developed and registered.9 
The use of the Bioject 2000 (Bioject) is limited because it requires a cartridge to function. An alternative 
is the Tropis (PharmaJet) which is a hand-held device that uses pressurized liquid stream.9 In our review, 
this device was as effective as the needle and syringe. This complements results of a study that was done 
in Pakistan.41 An intradermal adapter (West Pharmaceutical Services) and intradermal syringe (Star 
Syringe) have also been shown to be as effective as the BCG needle and syringe.42 Different studies have 
shown the programmatic feasibility of using these devices in door to door vaccination campaigns and 
one day vaccination campaigns.41,42 The cost of the device and the need to train vaccinators on how to 
use the devices should be considered. 
Before introducing f-IPV into vaccine schedules WHO encourages countries to consider programme 
feasibility.6 National health committees must decide on off the label use of f-IPV. Considering that other 
vaccines like rabies and influenza vaccines have been carried using fractional dosage,9.37 it is possible to 
use f-IPV on a national scale. Other operational needs required to integrate f-IPV in national 
immunisation schedules include policy formation and implementation, vaccine availability and cost, 
availability of human resources, adaptation of surveillance systems, training and dissemination of 
information, cold-chain management and maintenance of the integrity of the vaccine vial stopper.9,37 
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A joint statement released by the leaders of the GEPI committees stated that the Polio Eradication & 
Endgame Strategy 2013-2018 is now being revised and will extend up to 2023.46 As we progress towards 
global certification of polio eradication, f-IPV does have a role to play in ensuring sustained and 
affordable IPV supply. Notwithstanding the above considerations, India and Sri Lanka have shown that it 
is possible to use f-IPV at a national scale. 
The lack of data on randomisation and allocation concealment in half of the studies limited our 
assessment of selection bias. We complemented our confidence in the participant selection by looking 
at the characteristics of comparison groups. In all studies there were almost comparable. In extracting 
data for anti-polio 1, 2 and 3 titres, the standard deviation for the median antibody titre were not 
reported therefore, the 95% confidence interval were used to estimate the standard deviations. These 
figures enabled us to have approximated results that we could use. Our standard mean differences 
concurred with results from other studies. Different definitions of seroconversion were used by the 
authors. We tried our best to combine studies that had a similar definition. 
This systematic review and meta-analysis provided an evidence base that could be used by policy makers 
on deciding on adopting f-IPV in their national immunisation schedules. This evidence supports the 
replacement of bOPV with f-IPV. In the future, duration of humoral immunity and mucosal immunity are 
important areas of f-IPV research. 
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Table 1. Characteristics of studies included in the meta-analysis 
Study Country Years Design Participants Intervention  Comparator Outcome assessment 
Resik et al. 
(2010)20  
Cuba 2006-07 Clinical 
RCT 
Healthy male and 
female new-born 
infants from 3 
maternity hospitals 
and 15 vaccination 
sites in Camagüey 
Province.  
235 vaccinated with 
fractional-dose IPV 
(0.1mL, or 1/5 of a full 
dose of IPV). ID delivery 
at 6, 10 and 14wks using 
a needle-free jet injector 
(Biojector 2000, Bioject). 
236 vaccinated with full 
dose of IPV. IM delivery 
at 6, 10 and 14wks using 
a pre-filled syringe and 
needle. 
Seroconversion: modified neutralization assay 
for anti-polio 1, 2, and 3 antibody titers. Starting 
dilution = reciprocal titer of 8; seropositivity = 
reciprocal titer ≥ 8; maternal antibody half-life 
decay = 28 days. 
Antibody GMT: reported as the overall median 
polio antibody titre and median polio antibody 
titre for seroconverted individuals only. 
Mohammed 
et al. 
(2010)21  
Oman 2007 Clinical 
RCT 
Healthy male and 
female infants, 
recruited at birth, 
with a median age of 
62 days at first dose. 
From clinics in 5 sites 
in Oman. 
200 vaccinated with 
fractional-dose IPV (0.1 
ml, representing one 
fifth of a full dose). ID 
delivery at 2, 4 and 6M 
using a needle-free jet 
injector (Biojector 2000, 
Bioject). 
200 vaccinated with full-
dose IPV (0.5ml). IM 
delivery at 2, 4 and 6M 
using an auto-disable 
syringe and needle 
Seroconversion: modified neutralization assays 
for anti-polio 1, 2, and 3 antibody titers. Starting 
dilution = reciprocal titer of 8; seropositivity = 
reciprocal titer ≥ 8; maternal antibody half-life 
decay = 28 days. 
Antibody GMT: reported as median reciprocal 
titre. 
 
Cadorna-
Carlos et al. 
(2012)22-24  
Philippines 2008-09 Clinical 
RCT 
 
Primary series study: 
healthy male and 
female infants aged 
45.5days on average. 
Booster study: 
children, aged 15-
18M, who completed 
the primary series 
study. * 
Primary series study: 
118 vaccinated with 
fractional IPV dose 
(1/5th of the IM volume). 
ID delivery using needle 
and syringe at 6, 10 and 
14wks.   
Booster study: 113 
vaccinated at 15-18M. 
Primary series study: 
118 vaccinated with full 
dose; 0.5ml. IM delivery 
using pre-filled syringes 
with a 16-mm 25-gauge 
needle; at 6, 10 and 
14wks. 
Booster study: 112 
vaccinated at 15-18M. 
Seroconversion: seroneutralization assay for 
anti-polio 1, 2, and 3 antibody titers using wild-
type Salk strains. Lower limit of quantification = 
4 (1/dil); seroprotection = antibody titre ≥8 
(1/dil); maternal antibody half-life decay = 
28days. 
Antibody GMT: reported as geometric median 
titres for anti-polio 1, 2 and 3.  
. 
Estivariz et 
al. 
(2012)25  
 
 
 
 
 
India 2009 Community- 
based 
RCT 
Healthy male and 
female infants in high 
risk areas of 
Moradabad, who had 
received tOPV in RI 
and supplementary 
doses of mOPV1. 
Aged 6-9M. ꝉ 
202 vaccinated with GSK 
ID fractional-dose IPV 0.1 
mL (20% of the full dose). 
ID delivery of 1 dose at 5-
9M using a needle-free 
jet injector (Tropis, 
PharmaJet). 
 
204 vaccinated with GSK 
IM full dose 0.5ml. IM 
delivery of 1 dose at 5-
9M using a needle and 
syringe. 
Seroconversion: modified neutralization assays 
for anti-polio 1, 2, and 3 antibody titers. Titres 
less than the starting dilution = <8; titres more 
than the final dilution = ≥1448; maternal 
antibody half-life decay = 6M. 
Antibody GMT: reported as median reciprocal 
titres  
 
Resik et al. 
(2013)26  
Cuba 
 
 
2009 
 
 
Clinical 
RCT 
 
Healthy male and 
female infants 
recruited from 2M of 
age. From 13 
vaccination sites in 4 
districts of Camagüey 
Province, Cuba. 
160 vaccinated with 
fractional dose of IPV 
(0.1 ml, or one fifth of the 
full dose). ID delivery at 4 
and 8M using a needle-
free jet injector 
(Biojector 2000, Bioject) 
 160 vaccinated with full 
dose of IPV. IM delivery 
at 4 and 8M using an 
auto-disable syringe and 
needle 
Seroconversion: modified neutralization assay 
anti-polio 1, 2, and 3 antibody titer. Starting 
dilution = reciprocal titre of 8; seropositivity = 
reciprocal titer of ≥8; maternal antibody half-life 
decay = 30 days. 
Antibody GMT: reported as median reciprocal 
antibody titres  
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Anand et al. 
(2015)27,28  
Bangladesh 
 
2012-13 RCT Healthy male and 
female infants with a 
median age of 44 
days and a range of 
41-53days from 5 
different sections of 
Mirpur.ⱡ 
2 arms vaccinated with 
ID f-IPV (0.1 ml) using 
microneedle injection 
(Nanopass Micronjet 
600).  
-164 vaccinated with f-
IPV only at 6 and 14wks.  
-216 vaccinated with  
f-IPV/bOPV. ID f-IPV at 6 
and 14wks and bOPV at 
10wks. 
162 vaccinated with IM 
IPV (0.5 ml) at 6 and 
14wks using a standard 
needle and syringe 
Seroconversion: microneutralization assays for 
anti-polio 1, 2, and 3 antibody titres. 
Seronegative = titers below a dilution of 1:8; 
highest measurable titer = 1:1448; maternal 
antibody half-life decay = 28 days. 
Antibody GMT: reported as reverse cumulative 
antibody titres presented using cumulative 
distribution graphs. 
 
Resik et al. 
(2015)29,30  
 
Cuba 2013 Clinical 
RCT 
Healthy male and 
female children aged 
between 12-20M in 
Camagüey Province 
who had received 2 
doses of OPV per 
Cuban immunisation 
policy 
4 arms (583 participants) 
vaccinated with 
fractional dose IPV 
(1/5th of full dose). ID 
delivery 1 dose at 12-
20M using 1 of 4 devices: 
BCG needle and syringe, 
Biojector 2000, Tropis ID 
jet injector and Bioject ID 
Pen injector. 
146 vaccinated with full 
IPV dose (0.5 mL). IM 
delivery 1 dose at 12-
20M using a needle and 
syringe. 
 
Seroconversion: standard neutralization assays 
for anti-polio 1, 2, and 3 antibody titres. 
Seropositivity = reciprocal titers ≥8; the highest 
dilution of sera = 1:11,300; maternal antibody 
half-life decay not reported. 
Antibody GMT: reported as median titres 
 
Clarke et al.  
(2016)31-33 
Gambia 2013-14 Clinical 
RCT 
Stage 1: healthy male 
and female infants 
with a mean age of 
9.5M who had 
received at least 3 
tOPV doses. 
Stage 2: participants 
who did not receive 
IPV in stage 1. § 
Stage 2 
378 vaccinated with ID 
fractional-dose (0.1 mL) 
IPV 1 dose at 10-12 M 
using either needle and 
syringe or Tropis ID jet 
injector. 
 
 
Stage 2 
376 vaccinated with IM 
full-dose (0.5 mL) IPV 1 
dose at 10-12 M using 
either needle and syringe 
or Stratis jet injector 
Seroconversion:  neutralisation assays anti-
polio 1, 2, and 3 antibody titres. Starting dilution 
= 1 in 8; seropositivity = reciprocal titre ≥8; 
maternal antibody half-life decay not reported. 
Antibody GMT: Estimated using the 
mean/median of log2-transformed titre data and 
reported as antibody titres. 
RCT = randomised controlled trial, RI = routine immunisation, GSK = GlaxoSmithKline, IPV = inactivated polio vaccine, f-IPV = fractional dose IPV, mOPV1 = monovalent oral polio vaccine type 1, tOPV = trivalent 
oral polio vaccine, ID = intradermal, IM = intramuscular, GMT = geometric median antibody titres, dil = dilution, M = months,  wks = weeks, mins = minutes, hrs = hours, ml = millilitre, CI = confidence interval. 
*The study was located at the University of the East Ramon Magsaysay Memorial Medical Center, Manila, Philippines. ꝉ1002 participants were randomised to 5 arms, 2 arms which were relevant to the review 
are reported in table. Amongst these participants, a median of 7 mOPV1 doses and a median of 2 tOPV doses were administered before the trial vaccination. ⱡ975 participants were randomised to 5 arms, 3 
arms which were relevant to the review are reported in table. §Stage 1 assessed the interference associated with co-administering a full dose of IPV with measles-rubella vaccine and the yellow fever vaccine. 
Participants in stage 2 received single doses of measles-rubella vaccine and yellow fever vaccine alone or combined according to the group allocation in stage 1.  
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Table 2. Characteristics of on-going studies* 
 
Study ID Sponsors and 
collaborators 
Country Study 
design 
Start 
date 
Primary 
completion 
dateꝉ 
Recruitment 
status 
Population Intervention Comparator Main Outcomes 
NCT02847026 
 
CDC and 
International 
Centre for 
Diarrheal 
Disease 
Research, 
Bangladesh 
Bangladesh RCT 
 
Sept. 
2016 
May 2017 Completed Healthy 
infants aged 
between 42-
48 days  
Fractional IPV (f-
IPV; 0.1 mL, one-
fifth the full-
dose). f-IPV only; 
3 doses at 6, 14 
and 22wks. F-
IPV/IPV; 2 arms: 
IPV at 6wks, f-IPV 
at 22wks and IPV 
at 14wks, f-IPV at 
22wks. 
0.5 mL, full-dose, 
IPV at 14 and 
22wks 
1. Seroconversion 
and priming after 
vaccination with f-
IPV compared to IPV 
2. Seroconversion 
after rotavirus 
vaccination 
(Each intervention 
has 2 arms 
comparing 2 
rotavirus vaccines) 
NCT03239496 
 
FIDEC 
Corporation 
and Bill and 
Melinda 
Gates 
Foundation 
Panama 
and the 
Dominican 
Republic 
RCT 
 
Oct. 
2017 
Nov. 2018 Completed Healthy 6 
weeks old 
Infants  
Fractional-dose 
IPV ID delivery, 3 
doses at 10, 14 
and 16wks and 2 
doses at 14 and 
16wks 
IM IPV, 3 doses at 
10, 14 and 16wks 
and 2 doses at 14 
and 16wks 
Seroconversion 
after vaccination 
with f-IPV or IPV 
and comparison 
between 2 and 3 
doses.  
NCT03286803 
 
Aga Khan 
University and 
World Health 
Organisation 
Pakistan 
 
RCT 
 
Aug. 
2017 
Apr. 2019 Active, not 
recruiting 
2 groups of 
healthy 
infants aged 
between 
14wks and 
10M  
Fractional dose 
(0.1ml); 1 group 
will receive 1 
dose at 14weeks 
and the other at 
9M 
Full dose (0.5ml); 
1 group will 
receive 1 dose at 
14weeks and the 
other at 9 
Seroconversion and 
immune response 
across study arms 
and at different 
time points 
*Trial status reported by investigators as of 28 January 2019 under the ClinicalTrials.gov trial registry. ꝉFinal data collection date for primary outcome measure. References for on-going trials are outlined in 
appendix A table 3. 
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Table 3: Excluded full text articles and reasons for exclusion 
 
Study ID Reason for exclusion 
 
Nirmal et al. 
(1998) 
The study compared immune responses at different number and interval of f-IPV doses.  There was no 
full dose arm. 
Samuel et al. 
(1991) 
The study had only one arm with fractional doses. There was no full dose arm.  
Samuel et al. 
(1992) 
The study had only one arm with fractional doses. There was no full dose arm 
Guoyang et al. 
(2012) 
The study compared immunogenicity of 3 different formulations of a Sabin derived IPV to the Salk 
based IPV.   
Quiambao et 
al. (2012) 
The study compared immunogenicity of a hexavalent vaccine with different formulations of the IPV 
component to co-administration with full dose IPV. 
Okada et al. 
(2013) 
Phase 2 and 3 clinical studies that assessed the immunogenicity of a new combined vaccine containing 
Sabin derived IPV derived at different reduced antigen doses. 
Verdijk et al. 
(2014) 
The study compared the immunogenicity of 3 different formulation of a new Sabin based IPV vaccine 
with or without aluminium adjuvant to Salk based IPV. 
Saleem et al. 
(2017) 
The study 3 comparison groups all given f-IPV using one of three intradermal devices. There was no full 
dose arm. 
Sun et al. 
(2017) 
Assesses the neutralising capacity of the Sabin derived IPV vaccine with 3 different formulations to OPV 
and Salk based IPV. 
Rivera et al. 
(2017) 
Compares the immunogenicity of aluminium adjuvanted IPV vaccine with reduced antigen doses given 
as 0.5ml injections versus the full dose IPV  
Ye et al. 
(2018) 
Compares the safety and immunogenicity of two different sequential schedules Sabin derived IPV and 
bOPV. 
NCT01048190  Completed trial that assessed the safety and immunogenicity of 3 formulations of Sabin derived IPV 
compared to a placebo.  
NCT02967783  A trial with 3 comparison groups all given f-IPV using one of three intradermal devices. There was no 
full dose arm.  
NCT03032419.  Compares safety and immunogenicity of adjuvanted reduced doses of Sabin derived IPV to non-
adjuvanted full dose Sabin derived IPV. 
NCT03025750  Compares safety and immunogenicity of adjuvanted reduced doses of Sabin derived IPV to non-
adjuvanted full dose Sabin derived IPV.  
NCT03169725 
 
Compares a reduced form of a new Sabin based IPV vaccine versus full dose Salk based IPV.  
NCT03092791 Compares a reduced form of a new Sabin based vaccine versus full dose Salk based vaccine.  
 
References for excluded full text articles are outlined in appendix A table 4 
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Table 4. Summary of risk of bias in included studies 
 
 Resik  
et al. 
(2010)20 
Mohammed 
et al. 
(2010)21 
Cadorna-
Carlos  
et al.  
(2012)22 
Estivariz 
et al. 
(2012)25 
Resik  
et al. 
(2013)26 
Anand  
et al. 
(2015)27 
Resik  
et al. 
(2015)29 
Clarke  
et al. 
(2016)31 
Random sequence generation 
(selection bias)         
Allocation concealment 
(selection bias)         
Blinding of outcome assessment 
(detection bias)         
Incomplete outcome data 
(attrition bias)         
Selective reporting  
(reporting bias)         
Other bias 
         
Low risk; Unclear risk; High risk 
 
 
Table 5. GRADE summary of findings for the effects of fractional-dose inactivated poliovirus vaccine 
 
Population: Healthy infants 
Settings: Bangladesh, Cuba, The Gambia, India, Oman and Philippines  
Intervention: Vaccination with fractional-dose inactivated poliovirus vaccine 
Comparison: Vaccination with standard dose inactivated poliovirus vaccine 
Outcomes Illustrative comparative effects 
(95% CI) 
Relative effect 
(95% CI) 
No of 
Participants 
(studies) 
Certainty of 
evidence 
(GRADE) Standard dose Fractional-dose 
Seroconversion rates; 
3 standard doses vs 3 f-IPV doses 
83 per 100 
(71 to 95) 
79 per 100 
(76 to 83) 
RR 0.95 
(0.91 to 1.00) 
1107 
(3 RCTs) 
⊕⊕⊕⊕ 
High 
Seroconversion rates; 
2 standard doses vs 2 f-IPV doses 
78 per 100 
(57 to 95) 
68 per 100 
(55 to 82) 
RR 0.87 
(0.71 to 1.05) 
1517 
(4 RCTs) 
⊕⊕⊝⊝ 
Low * 
Seroconversion rates; 
1 standard doses vs 1 f-IPV doses 
49 per 100 
(26 to 87) 
30 per 100 
(25 to 36) 
RR 0.61 
(0.50 to 0.73) 
2815 
(7 RCTs) 
⊕⊕⊕⊝ 
Moderate ꝉ 
CI = confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; f-IPV = fractional dose 
inactivated poliovirus vaccine; RR: Risk ratio; RCTs = Randomised controlled trials. 
* Downgraded because of a high level of inconsistency (high level of heterogeneity (I2 =93%)) 
ꝉ Downgraded because of a moderate level of inconsistency (moderate level of heterogeneity (I2 =77%)) 
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Figure 1.  PRISMA flow chart for study selection* 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
IPV = inactivated poliovirus vaccine, f-IPV = fractional-dose IPV. Study selection done in duplicate. *16 sites searched. 
Databases and sites searched, and the number of articles retrieved shown in appendix A table 2. 
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Additional records identified (grey 
literature, websites, references) 
(n = 133) 
Total records identified 
(n = 1340) 
Records screened 
(n = 858) 
Records excluded 
(n = 824) 
Full-text articles assessed 
for eligibility 
(n = 34) 
Full-text articles excluded, 
with reasons 
(n = 17) 
5 = f-IPV only schedules, 
full dose IPV not given 
12 = focused on reduced 
antigen doses using Sabin 
derived IPV.  
Eligible studies 
(n = 17) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 8 studies published in 
14 articles) 
Duplicates removed 
(n = 482) 
On-going studies excluded 
(n = 3) 
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Figure 2. Meta-analysis of seroconversion proportions for poliovirus type 2 by number of doses 
 
 
Three fractional doses compared to three full doses of IPV 
 
Two fractional doses compared to Two full doses of IPV 
 
One fractional dose compared to one full dose of IPV 
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Figure 3. Meta-analysis of standard median antibody titres differences for poliovirus type 2 by number of doses 
 
 
Three fractional doses compared to three full doses of IPV 
 
Two fractional doses compared to two full doses of IPV 
 
One fractional dose compared to one full dose of IPV 
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Figure 4.  Subgroup analysis of seroconversion proportions for poliovirus type 2 by number of doses and immunisation 
schedules 
Three fractional doses compared to three full doses of IPV by immunisation schedule 
 
Two fractional doses compared to two full doses of IPV immunisation schedule 
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APPENDIX A: RECORD SELECTION AND BIAS ASSESSMENT. 
Table 1: Search strategy created using PubMed and adapted for other databases 
 
#1: Poliovirus Vaccine, Inactivated [MeSH] OR inactivated polio vaccine OR inactivated poliovirus vaccine 
OR SALK OR IPV OR eIPV OR killed vaccine. 
#2: Injections, Intradermal [MeSH] OR Injections, Intramuscular [MeSH] OR fractional dosing OR 
Fractionated dosing OR drug dose comparison OR intradermal OR intramuscular OR dose OR dosage. 
#3: Dose-Response Relationship, Immunologic [MeSH] OR Antibody Formation [MeSH] OR Seroconversion 
[MeSH] OR Immunogenicity OR Immune response OR Seroconversion OR potency OR antibody formation 
OR antibody response. 
#4: (#1 AND #2 AND #3). 
#5: Animals NOT Human 
#6: (#4 NOT #5) 
 
 
 
Table 2: Number of records retrieved from databases and search for grey literature. 
 
Database Articles 
retrieved 
Grey Literature Articles 
retrieved 
PubMed/Medline 609 ClinicalTrials.gov 42 
Cochrane* 322 WHO International Clinical Trials Registry Platform 11 
Scopusꝉ 84 PapersFirst (OCLC) 8 
SCI‡  53 Proceedings (OCLC)  52 
AWI 54 PDQ-Evidence 1 
CINAHL 38 ProQuest Dissertations & Theses A&I 10 
Health Source: Nursing/Academic 47 DART-Europe E-theses Portal (DEEP) 5 
  Networked Digital Library of Theses and 
Dissertations 
4 
Total articles 1207  133 
SCI = Science Citation Index, AWI = Africa Wide Index, CINAHL = Cumulative Index of Nursing and Allied Health Literature, OCLC = Online Computer 
Library Center. *Cochrane = CENTRAL, CDSR and DARE. ꝉScopus searched for EMBASE records and 631 articles indexed by Medline excluded. 
‡1057 records indexed by Medline and tagged zoological excluded. Databases were searched on the 10th of April 2018 and grey literature was 
searched for on the 11th of April 2018 with no date, language or publication restrictions. Records from WHO and GPEI websites and reference lists 
of included studies, related reviews, and relevant WHO vaccine position papers were already included in other searches. Conference Proceedings 
Citation Index is part of SCI. 
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Table 3. References for on-going trials 
 
Study ID References 
 
NCT02847026 CDC and International Centre for Diarrheal Disease Research, 
Bangladesh. Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study. 2016. 
https://ClinicalTrials.gov/show/NCT02847026 (accessed Jan. 29, 2019). 
 
NCT03239496 FIDEC Corporation and Bill and Melinda Gates Foundation. A Study to Evaluate Immunogenicity of 
Intramuscular Full-Dose and Intradermal Fractional Dose of IPV.2017. 
https://ClinicalTrials.gov/show/NCT03239496 (accessed Jan. 29, 2019). 
 
NCT03286803 
 
Aga Khan University and World Health Organisation. Comparison of Immunity Following IPV Versus fIPV: A 
Community Based Randomized Controlled Trial in Pakistan. 2017. 
https://ClinicalTrials.gov/show/NCT03286803 (accessed Jan. 29, 2019). 
 
Table 4. References for excluded studies 
 
Study ID Reference 
 
Nirmal et al. 
(1998) 
Nirmal S, Cherian T, Samuel BU, Rajasingh J, Raghupathy P, John TJ. Immune response of infants to 
fractional doses of intradermally administered inactivated poliovirus vaccine. Vaccine 1998; 16(9-10): 928-
31.  
Samuel et al. 
(1991) 
Samuel BU, Cherian T. Immune response to intradermally injected inactivated poliovirus vaccine. Lancet 
1991; 338(8763): 343. 
Samuel et al. 
(1992) 
Samuel BU, Cherian T, Rajasingh J, Raghupathy P, John TJ. Immune response of infants to inactivated 
poliovirus vaccine injected intradermally. Vaccine 1992; 10(2): 135. 
Guoyang et al. 
(2012) 
Guoyang L, Rongcheng L, Changgui L, et al. Safety and Immunogenicity of Inactivated Poliovirus Vaccine 
Made From Sabin Strains: A Phase II, Randomized, Positive-Controlled Trial. J Infect Dis 2012; 205(2): 237-
43. 
Quiambao et al. 
(2012) 
Quiambao B, Van Der Meeren O, Kolhe D, Gatchalian S. A randomized, dose-ranging assessment of the 
immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-
hepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-
administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers. Hum Vaccin 
Immunother 2012; 8(3): 347-54. 
Okada et al. 
(2013) 
Okada K, Miyazaki C, Kino Y, Ozaki T, Hirose M, Ueda K. Phase II and III Clinical Studies of Diphtheria-
Tetanus-Acellular Pertussis Vaccine Containing Inactivated Polio Vaccine Derived from Sabin Strains (DTaP-
sIPV). J Infect Dis 2013; 208(2): 275-83. 
Verdijk et al. 
(2014) 
Verdijk P, Rots NY, van Oijen MG, et al. Safety and immunogenicity of a primary series of Sabin-IPV with 
and without aluminium hydroxide in infants. Vaccine 2014; 32(39): 4938-44. 
Saleem et al. 
(2017) 
Saleem AF, Mach O, Yousafzai MT, et al. Needle adapters for intradermal administration of fractional dose 
of inactivated poliovirus vaccine: Evaluation of immunogenicity and programmatic feasibility in Pakistan. 
Vaccine 2017; 35(24): 3209-14. 
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Sun et al. (2017) Sun M, Li C, Xu W, et al. Immune Serum From Sabin Inactivated Poliovirus Vaccine Immunization 
Neutralizes Multiple Individual Wild and Vaccine-Derived Polioviruses. Clin Infect Dis 2017; 64(10): 1317-
25.  
Rivera et al. 
(2017) 
Rivera L, Pedersen RS, Pena L, et al. Immunogenicity and safety of three aluminium hydroxide adjuvanted 
vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young 
infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and 
controlled dose investigation trial. Lancet Infect Dis 2017; 17(7): 745-53. 
Ye et al. (2018) Ye H, Huang T, Ying ZF, et al. [Comparing the immunogenicity and safety of sequential inoculation of sIPV 
followed by bOPV (+) in different dosage forms]. Zhonghua Yu Fang Yi Xue Za Zhi 2018; 52(1): 43-9. 
NCT01048190  Chinese Academy 2008. The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made from 
Sabin Strains., 2008. https://ClinicalTrials.gov/show/NCT01048190 (accessed Apr. 28, 2018). 
NCT02967783  Medical Research Council Unit, The Gambia 2017. Prevention. A Campaign-based ID fIPV Administration 
Trial. 2017. https://ClinicalTrials.gov/show/NCT02967783 (accessed Apr. 29, 2018).  
NCT03032419.  Statens Serum Institut 2017. Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio 
Vaccine Given at 6, 10, 14 Weeks and 9 Months., 2017. https://ClinicalTrials.gov/show/NCT03032419 
(accessed Apr. 28, 2018). 
NCT03025750  . Statens Serum Institut 2017. Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio 
Vaccine in 2, 4, 6 Months of Age., 2017. https://ClinicalTrials.gov/show/NCT03025750 (accessed Apr. 28, 
2018).  
NCT03169725 
 
LG Chem 2017. A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis 
Vaccine in Healthy Infants. 2017. https://clinicaltrials.gov/show/NCT03169725 (accessed Apr. 28, 2018). 
NCT03092791 Takeda 2017. IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and 
Adults., 2017. https://ClinicalTrials.gov/show/NCT03092791 (accessed Apr. 28, 2018). 
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Table 5. Bias judgements adapted from the Cochrane Handbook of Systematic Reviews 
Random sequence generation (selection bias): Random- every participant has an equal probability of being allocated to any of 
the treatment arms. 
Low risk:  
Methods of random sequence 
generation 
1. computer generated system/block 
randomisation  
2. random number table 
3. drawing of lots 
4. tossing of coin 
5. shuffling of cards  
6. throwing dice as  
High risk: 
Methods of random sequence 
generation 
1. Dates 
2. Medical record numbers 
3. Order of recruitment 
4. Days of the week 
5. Any Quasi-random allocation  
6.Allocation based on individual’s 
judgement (clinician, laboratory result, 
availability of treatment options) 
Unclear risk: 
Method not described or described in 
insufficient detail to make a decision. 
Allocation concealment (selection bias): Concealment- the person who is allocating treatment options is prevented from 
knowing the allocation of the next person who has been enrolled. 
Low risk: 
Methods of concealment 
1. Controlled by central independent 
unit 
2. Sealed opaque envelopes  
3. On-site computer-generated 
computer secure and locked 
4. Sequentially numbered drug 
packages with the same schedules, 
appearance and administration of 
treatment allocation 
5. Block randomisation 
High Risk: 
Methods of concealment 
1. Alternation 
2. Dates and registration numbers 
3. Any method were allocation was not 
concealed, allocation was known to 
both investigator and participants 
 
Unclear risk: 
Method not described or described in 
insufficient detail to make a decision. 
Blinding of personnel and participants (performance bias): Systematic difference between comparison groups because of 
knowledge of the treatment allocation by personnel and participants. 
 
Remove this domain because blinding is impossible with the different routes of vaccine administration in the comparison arms 
(IM vs ID) 
Blinding of outcome assessment (measurement bias): Systematic difference between comparison groups because of a 
difference in the application of standards of measuring the outcome due to knowledge of treatment options by outcome 
assessors.  
Low risk: 
Methods of blinding 
1. Adequate description of blinding of 
assessors and no chance of blinding 
being broken 
2. If the lab analysis was done in 
another country, consider it low risk  
High risk: 
Methods of blinding 
1. No blinding or incomplete blinding of 
assessors  
2. Assessors are blinded but blinding is 
broken  
Unclear risk: 
Method not described or described in 
insufficient detail to make a decision 
Incomplete outcome data (Attrition bias): Systematic differences between comparison groups in the amount, nature and 
handling of retention of study participants. 
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Low risk: 
Amount, nature and methods of 
handing missing data. 
1. there are no missing data 
2. the reasons for the missing data are 
unrelated to the study outcome 
3. The proportion and reasons for 
missing data are similar amongst all 
comparison groups. 
4. Proportion of missing data is not 
enough to bias the effect size (</=10 % 
differential loss to follow up) 
5. the study used appropriate methods 
that account for the missing data. 
High risk: 
Amount, nature and methods of 
handing missing data. 
1. The reasons for the missing data are 
related to the study outcome 
2. The proportion and reasons for 
missing data are significantly different 
amongst the comparison groups. >10 % 
difference between comparison groups 
3. ITT used when there is significant 
departure from treatment allocation 
after randomisation 
4. The study used inappropriate 
methods to impute the data. 
 
Unclear risk: 
Method not described or described in 
insufficient detail to make a decision. 
 
Selective outcome reporting: Systematic differences between reported and findings not reported due to selective reporting.  
 
Low risk: 
1. Study outcomes (primary and 
secondary) are reported as per pre-
specifications  
 
High risk: 
1. Prespecified outcomes are not 
reported. 
2. Use of methods of measurement and 
analysis of a primary outcome that was 
not prespecified. 
3. Inclusion of a primary outcome that 
was not in the protocol without a valid 
reason. 
Unclear risk: 
Method not described or described in 
insufficient detail to make a decision 
Other Bias: Bias due to other reasons not stated in this table 
 
Low risk: 
Absence of bias in the study 
 
High risk: 
Presence of a factor that could introduce 
bias 
Unclear risk: 
Method not described or described in 
insufficient detail to make a decision 
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APPENDIX B: SUPPLEMENTARY ANALYSIS 
Figure 1. Meta-analysis of seroconversion proportions for poliovirus type 1 by number of doses 
 
 
Three fractional doses compared to three full doses of IPV 
 
Two fractional doses compared to two full doses of IPV 
 
One fractional dose compared to One full dose of IPV 
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Figure 2. Meta-analysis of seroconversion proportions for poliovirus type 3 by number of doses 
 
 
Three fractional doses compared to three full doses of IPV 
 
Two fractional doses compared to two full doses of IPV 
 
One fractional dose compared to one full dose of IPV 
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Figure 3. Meta-analysis of standard median antibody titres differences for poliovirus type 1 by number of doses 
 
 
Three fractional doses compared to three full doses of IPV 
 
Two fractional doses compared two 2 full doses of IPV 
 
One fractional dose compared to one full dose of IPV 
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Figure 4. Meta-analysis of standard median antibody titres differences for poliovirus type 3 by number of doses 
 
 
Three fractional doses compared to three full doses of IPV 
 
Three fractional doses compared to three full doses of IPV 
 
Three fractional dose compared to three full dose of IPV 
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Figure 5. Analysis of adverse events 
 
Serious adverse effects 
 
 
5.1 Serious adverse effects 
 
Local adverse events 
 
 
5.2 Pain/tenderness 
 
5.3 Redness/erythema 
 
5.4 Swelling/induration 
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Systemic adverse events 
 
5.5 Fever 
 
5.6 Loss of appetite 
 
5.7 Vomiting 
 
5.8 Irritability 
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5.9 Drowsiness 
 
5.10 Excessive crying 
 
5.11 Diarrhoea 
 
 
 
Table. 1 Description of severe adverse effects 
Mohammed et al. 
201027 
Reported SAE we due to 42 hospitalisations: 18 were vaccinated with f-IPV and 24 were 
vaccinated with full dose IPV. 39 had diarrhoea and upper respiratory tract infections, 1 
had anaemia, 2 were admitted after a fall and 5 of the 42 hospitalisations occurred 
before vaccination. 
Anand et al. 201531 3 infants died. 1 received f-IPV only and 2 received sequential f-IPV and bOPV. All deaths 
were investigated and were not related to IPV vaccination. The causes of death were 
Sudden infant death syndrome, pneumonia and infantile seizures. 
1 infant who received sequential fractional-dose IPV only and bOPV had severe diarrhoea 
while the another 2 who received full dose IPV had severe meningitis and diarrhoea. 
SAE= severe side effects, IPV = inactivated polio vaccine, f-IPV = fractional-dose, bOPV = bivalent OPV 
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Figure 6.  Subgroup analysis of seroconversion proportions for poliovirus type 2 by number of doses and timing of first 
dose 
6.1. Three fractional doses compared to three full doses of IPV by timing of first dose 
 
6.2. Two fractional doses compared to two full doses of IPV timing of first dose 
 
6.3. One fractional dose compared to one full dose of IPV timing of first dose 
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Figure 7.  Subgroup analysis of seroconversion proportions for poliovirus type 2 by number of doses and interval between 
2 doses 
Three fractional doses compared to three full doses of IPV by interval between 2 doses 
 
Two fractional doses compared to two full doses of IPV by interval between 2 doses 
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Figure 8. Subgroup analysis of seroconversion after 2 fractional doses compared to 2 full doses of IPV per poliovirus type 
by intradermal devices 
Poliovirus type 1 by intradermal device 
 
Poliovirus type 2 by intradermal device 
 
Poliovirus type 3 by intradermal device 
 
 
Section D: Appendices 
92 
 
Figure 9. Subgroup analysis of seroconversion after 2 fractional doses compared to 2 full doses of IPV per poliovirus type 
by country income status 
Poliovirus type 1 by country income status 
 
Poliovirus type 2 by country income status 
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Poliovirus type 3 by country income status 
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Figure 10. Subgroup analysis of seroconversion after 1 fractional dose compared to 1 full dose of IPV per poliovirus type by 
ID devices at 6 weeks 
Poliovirus type 1 by ID device at 6 weeks 
 
Poliovirus type 2 by ID device at 6 weeks 
 
Poliovirus type 3 by ID device at 6 weeks 
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Figure 11. Sub group analysis of seroconversion after 1 fractional dose compared to 1 full dose of IPV per poliovirus type by 
ID devices at 10-12M 
Poliovirus type 1 by ID device at 10-12M 
 
Poliovirus type 2 by ID device at 10-12M 
 
Poliovirus type 3 by ID device at 10-12M 
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Figure 12. Sub group analysis of seroconversion after 1 fractional dose compared to 1 full dose of IPV per poliovirus type by 
ID devices at 12-20M 
Poliovirus type 1 by ID device at 12-20M 
 
Poliovirus type 2 by ID device at 12-20M 
 
Poliovirus type 3 by ID device at 12-20M 
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Figure 13. Meta-analysis of poliovirus shedding after OPV challenge by timing of outcome measurements f-IPV only 
Poliovirus type 1 
 
Poliovirus type 2 
 
Poliovirus type 3 
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Figure 14. Meta-analysis of poliovirus shedding after OPV challenge by timing of outcome measurements f-IPV/bOPV 
Poliovirus type 1 
 
Poliovirus type 2 
 
Poliovirus type 3 
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Missing data excluded in the analysis/ according to author’s analysis 
Figure 15. Meta-analysis of seroconversion after 3 fractional doses compared to 3 full doses of IPV per poliovirus type 
Poliovirus type 1 
 
Poliovirus type 2 
 
Poliovirus type 3 
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Figure 16. Meta-analysis of seroconversion after 2 fractional doses compared to 2 full doses of IPV per poliovirus type 
Poliovirus type 1 
 
Poliovirus type 2 
 
Poliovirus type 3 
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Figure 17. Meta-analysis of seroconversion after 1 fractional dose compared to 1 full doses of IPV per poliovirus type 
Poliovirus type 1 
 
Poliovirus type 2 
 
Poliovirus type 3 
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Fixed effects model 
Figure 18. Meta-analysis of seroconversion after 3 fractional doses compared to 3 full doses of IPV per poliovirus type 
Poliovirus type 1 
 
Poliovirus type 2 
 
Poliovirus type 3 
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Figure 19. Meta-analysis of seroconversion after 2 fractional doses compared to 2 full doses of IPV per poliovirus type 
Poliovirus type 1 
 
Poliovirus type 2 
 
Poliovirus type 3 
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Figure 20. Meta-analysis of seroconversion after 1 fractional dose compared to 1 full dose of IPV per poliovirus type 
Poliovirus type 1 
 
Poliovirus type 2 
 
Poliovirus type 3 
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APPENDIX C: PRISMA CHECKLIST AND DATA EXTRACTION FORM 
Section/topic  # Checklist item  
Reported 
on page 
#  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  47 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data 
sources; study eligibility criteria, participants, and interventions; study appraisal and 
synthesis methods; results; limitations; conclusions and implications of key findings; 
systematic review registration number.  
48 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  50,51 
Objectives  4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design (PICOS).  
51,52 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web 
address), and, if available, provide registration information including registration 
number.  
54 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used as criteria 
for eligibility, giving rationale.  
52 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact 
with study authors to identify additional studies) in the search and date last 
searched.  
Appendix 
A table 2 
Search  8 Present full electronic search strategy for at least one database, including any limits 
used, such that it could be repeated.  
Appendix 
A table 1 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in 
systematic review, and, if applicable, included in the meta-analysis).  
52 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, independently, 
in duplicate) and any processes for obtaining and confirming data from 
investigators.  
52 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding 
sources) and any assumptions and simplifications made.  
Appendix 
C 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including 
specification of whether this was done at the study or outcome level), and how this 
information is to be used in any data synthesis.  
53 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  53 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, 
including measures of consistency (e.g., I2) for each meta-analysis.  
53 
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence 
(e.g., publication bias, selective reporting within studies).  
54 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, 
meta-regression), if done, indicating which were pre-specified.  
53 
RESULTS 
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Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the 
review, with reasons for exclusions at each stage, ideally with a flow diagram.  
54 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study 
size, PICOS, follow-up period) and provide the citations.  
54,55 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level 
assessment (see item 12).  
58, 70 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple 
summary data for each intervention group (b) effect estimates and confidence 
intervals, ideally with a forest plot.  
72-74, 
Appendix 
B 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and 
measures of consistency.  
55-57 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  70 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, 
meta-regression [see Item 16]).  
57, 58 
Appendix 
B 
DISCUSSION  
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each main 
outcome; consider their relevance to key groups (e.g., healthcare providers, users, 
and policy makers).  
58,59 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level 
(e.g., incomplete retrieval of identified research, reporting bias).  
61 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and 
implications for future research.  
61 
FUNDING  
Funding  27 Describe sources of funding for the systematic review and other support (e.g., 
supply of data); role of funders for the systematic review.  
54, 61 
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Data Extraction Form Version 3 
Review Title: A systematic review and meta-analysis of fractional dose compared to standard dose inactivated polio vaccination in children. 
Study ID  
Person extracting data  Data of extraction  
Person cross checking  Date of data cross 
checking 
 
 
Section A: Source 
Section B: Study eligibility 
Section C: Full text data extraction eligibility  
Section D: Methods of the study 
Section E: Study characteristics - Setting of the study and Participant characteristics 
Section F: Study characteristics - Interventions 
Section G: Study characteristics - Outcomes and comparison groups 
Section H: Data and results 
Section I: Bias assessment 
Section J: Additional information required 
Section K: Bibliography search 
A. Source 
Title  
Published Yes:        ☐                       No:       ☐        
Year of publication  
First Author  
Contact details  
Full citation  
Notes  
 Eligibility criteria Evaluation 
Yes             No          Unclear Not 
                                                                     reported  
Location in text or source 
Study design    
 Randomised Control Trial ☐ ☐ ☐ ☐  
 Quasi-Randomised Control Trial ☐ ☐ ☐ ☐  
 Cohort  ☐ ☐ ☐ ☐  
 Case Control ☐ ☐ ☐ ☐  
 Other Specify:  ☐ ☐ ☐ ☐  
Participants    
 ≤ 5years ☐ ☐ ☐ ☐  
Intervention    
 Administration of one or more fractional doses 
of inactivated polio vaccine 
☐ ☐ ☐ ☐  
Comparison    
 Administration of a full dose of inactivated polio 
vaccine 
☐ ☐ ☐ ☐  
Outcome    
Primary    
 Assess for polio type 1, type 2 and type 3 
seroconversion rates  
☐  ☐ ☐ ☐  
 Assess for polio type 1, type 2 and type 3 
geometric titres 
☐ ☐ ☐ ☐  
Secondary    
 Assess for adverse events ☐ ☐ ☐ ☐  
 Assess for vaccine associated paralytic 
poliomyelitis 
☐ ☐ ☐ ☐  
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B. Study Eligibility 
 
 C: Final set of articles to be included in the review 
Overall decision Include: ☐                             Exclude: ☐                           Not sure: ☐ 
Reason for exclusion  
Notes  
 
DO NOT PROCEED IF STUDY EXCLUDED FROM REVIEW 
 
D: Methods of the study 
  Location in the text or source or 
Notes 
Aim/s of the study stated 
And objectives 
Yes: ☐            No: ☐            Unclear: ☐            Not reported: ☐  
 
Aim/s   
 Primary objectives   
Secondary objectives   
Duration of study   
Study design   
Number of study arms    
Sample size (Enrolled and Randomised)   
Power calculation 
Sample size achieved 
Yes: ☐            No: ☐             Unclear: ☐             Not reported: ☐ 
Yes: ☐     No: ☐       Unclear: ☐          Not reported: ☐ 
 
 
 
Notes about Power calculation and or/ 
sample size  
  
Data Analysis Intention to treat: ☐ Per protocol: ☐ Unclear: 
☐ 
 
Consumer involvement Yes: ☐            No: ☐            Unclear: ☐             Not reported: ☐  
    If yes, which part of study   
Funding source stated or Donations Yes: ☐            No: ☐            Unclear: ☐             Not reported: ☐  
 
     If yes, specify   
Possible conflict of interest Yes: ☐            No: ☐           Unclear: ☐             Not reported: ☐  
 Note   
Ethics approval obtained Yes: ☐            No: ☐            Unclear: ☐            Not reported: ☐ p. 1346  
 
Informed consent obtained Yes: ☐            No: ☐            Unclear: ☐            Not reported: ☐ p. 1346 
 
Summary of study design  
Notes  
 
 E: Setting of the study and Participant characteristics 
  Location in the text or source 
Country where the study took place    
Country’s income status 
(as defined by the World Bank) 
Low: ☐  Lower middle: ☐   Upper Middle: ☐        High: ☐  
Setting (hospital, clinic, community)   
Description of participants 
 
Inclusion criteria   
Exclusion criteria   
 Assess for wild virus paralytic poliomyelitis ☐ ☐ ☐ ☐  
 Specified device used to deliver fractional doses ☐ ☐ ☐ ☐  
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Age median range in characteristics    
Summary of participant characteristics  
Notes  
 
Flow of participants in the study 
Before randomisation 
 
 Number of Participants 
 
Location in the text or source 
Screened (Recruited)   
Enrolled and Randomized    
Excluded   
Excluded-did not meet exclusion criteria   
Excluded-Refused to take part   
Reasons for exclusion other than those above    
After randomisation 
 
If multiple intervention, focus on comparison of interest Intervention 
 
Control 
 
Location in the text or source 
Number after randomisation    
Excluded post randomisation    
Reasons for exclusion 
Withdrawn    
Reasons for withdrawing    
Loss to protocol Violation     
Loss to follow up    
Reasons for loss to follow up    
Reasons for exclusion other than those stated above    
Number of participants who completed the study     
Excluded    
Reasons for exclusion from analysis    
Included in the analysis    
Summary of participant flow  
Notes   
 
F: Study Characteristics- Interventions 
Intervention characteristics 
  Intervention Location in 
the text 
Control Location in the 
text 
Definition of Intervention  
Intervention      
Manufacturer of the vaccine     
Vaccine Formulation    
     
 
Route of vaccine delivery 
 
intradermal: ☐ 
subcutaneous: ☐ 
intramuscular:☐  
other: 
 intradermal: ☐ 
subcutaneous: ☐ 
intramuscular: ☐ 
other: 
 
Who delivered the vaccine?     
Method and device (supplier) used to deliver 
the vaccine 
(First choose method of delivery in bold then 
device specified below. If option not 
available specify under other) 
Needle and syringe: ☐  
BCG delivery method: ☐                 
Mantoux delivery method: ☐  
Other:  
Microneedle injection: ☐  
MicronJet 600 (NanoPass): ☐ 
Other:  
   
Section D: Appendices 
110 
 
Jet injection: ☐  
Tropis (PharmaJet): ☐ 
ID Pen (Bioject): ☐ 
Other: Needle-free Biojector 2000, 
Bioject  
Microneedle arrays: ☐ 
ID Adapter (West Pharmaceutical 
Services): ☐ 
Other:  
Other:  
Number of doses given     
 Age at time of administration             
Interval between doses     
Notes  
 
Description and Schedules of Co-administered vaccine and drugs 
 Intervention Location 
in text 
Control Location 
In text 
Is the intervention co-administered with OPV or it is an 
IPV only schedule? 
OPV: ☐     
IPV only schedule: ☐  
Unclear: ☐ 
Other: 
 OPV: ☐     
IPV only schedule: ☐  
Unclear: ☐ 
Other:  
 
If yes to OPV co-administration,     
Relation with the delivery of the intervention  
 
Administered same time: ☐  
Sequential: ☐  
Other:  
 Administered same time: ☐  
Sequential: ☐  
Other: 
 
Type of OPV used 
 
bOPV: ☐    tOPV: ☐  
other: 
 bOPV: ☐ tOPV: ☐  
other: 
 
Number of OPV doses     
Timing of OPV doses 
 
 Dose 1:           
 Dose 2:            
 Dose 3:             
  Dose 1:           
 Dose 2:            
 Dose 3:             
 
Is the schedule 6, 10, 14 weeks: ☐ 
2, 4, 6 months: ☐  
Other: 
 6, 10, 14 weeks: ☐ 
2, 4, 6 months: ☐  
Other: 
 
Fully describe the schedule     
If yes to inactivated polio vaccine only schedule,   THE CONTROL ARM IS ALREADY 
A FULL DOSE IPV ONLY 
SCHEDULE 
 
Relation of the full dose IPV with the delivery of the 
intervention  
Administered same time: ☐  
Sequential: ☐  
Other: 
  
IPV dosage given at a single delivery    
Route of vaccine delivery   
Number of IPV doses   
Timing of IPV doses   
Is the schedule 
 
6, 10, 14 weeks: ☐ 
2, 4, 6 months: ☐  
Other: 
 
Fully describe the schedule   
Other vaccines or drugs given In both arms 
Name     
Relation with the delivery of the intervention      
dose     
Number of doses     
Timing of doses     
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Summary of intervention  
Notes  
 
G: Study characteristics – outcomes and comparison groups 
Outcome:   
Definition of outcome:  Is it the same for the all the 
comparison groups? 
Location in the text 
  Yes: ☐ No: ☐ Unclear: ☐  
Method of assessment  Yes: ☐  No: ☐  Unclear: ☐  
Timing of assessment  Yes: ☐  No: ☐  Unclear: ☐  
Statistic used   Yes: ☐  No: ☐  Unclear: ☐  
Length of follow up  Yes: ☐  No: ☐  Unclear: ☐  
Measures of following up non-
responders 
  Yes: ☐  No: ☐  Unclear: ☐  
Notes 
 
Summary of 
outcomes 
  
 
H: Data and results 
Seroconversion 
Polio type Intervention Control 
 Number of participants 
who seroconverted (n)  
Total participants (N) Number of participants 
who seroconverted (n)  
Total participants (N) 
Analysed Randomised Analysed Randomised 
Polio type 1       
Polio type 2       
Polio type 3       
Notes  
 
Median polio antibody titres 
Antibody 
titres 
Intervention Control 
 
 Median 
titres 
95%CI 
interval  
 
Total participants (N) Median 
titres 
95% CI interval  
  
Total participants (N) 
analysed Randm analysis Randm 
Polio type 1         
Polio type 2         
Polio type 3         
Notes  
 
Adverse events 
Adverse events Intervention  Control 
 Number of 
adverse 
events (n) 
Total Participants (N) Number of 
adverse 
events (n) 
Total participants (N) 
Analysed Randomised Analysed Randomised 
Local injection site reactions 
Pain/tenderness       
Redness/erythema       
Swelling/induration       
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General systemic reactions 
Fever       
Irritability       
Drowsiness       
Loss of appetite       
Vomiting       
Diarrhoea       
Other specify 
Severe adverse events 
Death       
Any other reactions 
above regarded as 
serious by author 
      
Notes  
 
I: Bias assessment 
Domain Risk of bias 
Low        High   Unclear 
Support for judgement Location in text of source 
Random sequence 
generation  
☐   ☐ ☐   
Allocation concealment ☐ ☐ ☐   
Blinding of personnel and 
participants 
☐ ☐ ☐   
Blinding of outcome assessment ☐ ☐ ☐   
Incomplete outcome data ☐ ☐ ☐   
Selective outcome reporting? ☐ ☐ ☐   
Other bias 
 
 
☐ ☐ ☐   
Overall validity judgement 
 
Low risk of bias        Moderate risk of bias           High risk of bias 
☐ ☐ ☐ 
Comment:  
 
J: Additional information required 
Author contact details  
Further information required Yes: ☐ No: ☐ 
Information required  
Correspondence successful Yes: ☐ No: ☐ 
Information received  
Date received  
Inclusion of additional unpublished data in the review  
Notes  
 
K: Bibliography search 
Citations that may be relevant to the study 
1. 
2. 
3. 
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